<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000971</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>16</s160></s100><s200><s210>1</s210><s211>2233</s211><s212>DNA</s212><s213>Influenza PR8-X</s213></s200><s400> 1agcgaaagca ggtactgatc caaaatggaa gattttgtgc gacaatgctt caatccgatg     60attgtcgagc ttgcggaaaa aacaatgaaa gagtatgggg aggacctgaa aatcgaaaca    120aacaaatttg cagcaatatg cactcacttg gaagtatgct tcatgtattc agattttcac    180ttcatcaatg agcaaggcga gtcaataatc gtagaacttg gtgatccaaa tgcacttttg    240aagcacagat ttgaaataat cgagggaaga gatcgcacaa tggcctggac agtagtaaac    300agtatttgca acactacagg ggctgagaaa ccaaagtttc taccagattt gtatgattac    360aaggagaata gatttatcga aattggagta acaaggagag aagttcacat atactatctg    420gaaaaggcca ataaaattaa atctgagaaa acacacatcc acattttctc gttcactggg    480gaagaaatgg ccacaaaggc agactacact ctcgatgaag aaagcagggc taggatcaaa    540accagactat tcaccataag acaagaaatg gccagcagag gcctctggga ttcctttcgt    600cagtccgaga gaggagaaga gacaattgaa gaaaggtttg aaatcacagg aacaatgcgc    660aagcttgccg accaaagtct cccgccgaac ttctccagcc ttgaaaattt tagagcctat    720gtggatggat tcgaaccgaa cggctacatt gagggcaagc tgtctcaaat gtccaaagaa    780gtaaatgcta gaattgaacc ttttttgaaa acaacaccac gaccacttag acttccgaat    840gggcctccct gttctcagcg gtccaaattc ctgctgatgg atgccttaaa attaagcatt    900gaggacccaa gtcatgaagg agagggaata ccgctatatg atgcaatcaa atgcatgaga    960acattctttg gatggaagga acccaatgtt gttaaaccac acgaaaaggg aataaatcca   1020aattatcttc tgtcatggaa gcaagtactg gcagaactgc aggacattga gaatgaggag   1080aaaattccaa agactaaaaa tatgaagaaa acaagtcagc taaagtgggc acttggtgag   1140aacatggcac cagaaaaggt agactttgac gactgtaaag atgtaggtga tttgaagcaa   1200tatgatagtg atgaaccaga attgaggtcg cttgcaagtt ggattcagaa tgagtttaac   1260aaggcatgcg aactgacaga ttcaagctgg atagagctcg atgagattgg agaagatgtg   1320gctccaattg aacacattgc aagcatgaga aggaattatt tcacatcaga ggtgtctcac   1380tgcagagcca cagaatacat aatgaagggg gtgtacatca atactgcctt gcttaatgca   1440tcttgtgcag caatggatga tttccaatta attccaatga taagcaagtg tagaactaag   1500gagggaaggc gaaagaccaa cttgtatggt ttcatcataa aaggaagatc ccacttaagg   1560aatgacaccg acgtggtaaa ctttgtgagc atggagtttt ctctcactga cccaagactt   1620gaaccacata aatgggagaa gtactgtgtt cttgagatag gagatatgct tataagaagt   1680gccataggcc aggtttcaag gcccatgttc ttgtatgtga gaacaaatgg aacctcaaaa   1740attaaaatga aatggggaat ggagatgagg cgttgcctcc tccagtcact tcaacaaatt   1800gagagtatga ttgaagctga gtcctctgtc aaagagaaag acatgaccaa agagttcttt   1860gagaacaaat cagaaacatg gcccattgga gagtccccca aaggagtgga ggaaagttcc   1920attgggaagg tctgcaggac tttattagca aagtcggtat tcaacagctt gtatgcatct   1980ccacaactag aaggattttc agctgaatca agaaaactgc ttcttatcgt tcaggctctt   2040agggacaacc ttgaacctgg gacctttgat cttggggggc tatatgaagc aattgaggag   2100tgcctgatta atgatccctg ggttttgctt aatgcttctt ggttcaactc cttccttaca   2160catgcattga gttagttgtg gcagtgctac tatttgctat ccatactgtc caaaaaagta   2220ccttgtttct act                                                      2233</s400><s200><s210>2</s210><s211>2341</s211><s212>DNA</s212><s213>Influenza PR8-X</s213></s200><s400> 2agcgaaagca ggcaaaccat ttgaatggat gtcaatccga ccttactttt cttaaaagtg     60ccaacacaaa atgctataag cacaactttc ccttatactg gagaccctcc ttacagccat    120gggacaggaa caggatacac catggatact gtcaacagga cacatcagta ctcagaaaag    180ggaagatgga caacaaacac cgaaactgga gcaccgcaac tcaacccgat tgatgggcca    240ctgccagaag acaatgaacc aagtggttat gcccaaacag attgtgtatt ggaggcgatg    300gctttccttg aggaatccca tcctggtatt tttgaaaact cgtgtattga aacgatggag    360gttgttcagc aaacacgagt agacaagctg acacaaggcc gacagaccta tgactggact    420ctaaatagaa accaacctgc tgcaacagca ttggccaaca caatagaagt gttcagatca    480aatggcctca cggccaatga gtctggaagg ctcatagact tccttaagga tgtaatggag    540tcaatgaaca aagaagaaat ggggatcaca actcattttc agagaaagag acgggtgaga    600gacaatatga ctaagaaaat gataacacag agaacaatgg gtaaaaagaa gcagagattg    660aacaaaagga gttatctaat tagagcattg accctgaaca caatgaccaa agatgctgag    720agagggaagc taaaacggag agcaattgca accccaggga tgcaaataag ggggtttgta    780tactttgttg agacactggc aaggagtata tgtgagaaac ttgaacaatc agggttgcca    840gttggaggca atgagaagaa agcaaagttg gcaaatgttg taaggaagat gatgaccaat    900tctcaggaca ccgaactttc tttcaccatc actggagata acaccaaatg gaacgaaaat    960cagaatcctc ggatgttttt ggccatgatc acatatatga ccagaaatca gcccgaatgg   1020ttcagaaatg ttctaagtat tgctccaata atgttctcaa acaaaatggc gagactggga   1080aaagggtata tgtttgagag caagagtatg aaacttagaa ctcaaatacc tgcagaaatg   1140ctagcaagca tcgatttgaa atatttcaat gattcaacaa gaaagaagat tgaaaaaatc   1200cgaccgctct taatagaggg gactgcatca ttgagccctg gaatgatgat gggcatgttc   1260aatatgttaa gcactgtatt aggcgtctcc atcctgaatc ttggacaaaa gagatacacc   1320aagactactt actggtggga tggtcttcaa tcctctgacg attttgctct gattgtgaat   1380gcacccaatc atgaagggat tcaagccgga gtcgacaggt tttatcgaac ctgtaagcta   1440cttggaatca atatgagcaa gaaaaagtct tacataaaca gaacaggtac atttgaattc   1500acaagttttt tctatcgtta tgggtttgtt gccaatttca gcatggagct tcccagtttt   1560ggggtgtctg ggatcaacga gtcagcggac atgagtattg gagttactgt catcaaaaac   1620aatatgataa acaatgatct tggtccagca acagctcaaa tggcccttca gttgttcatc   1680aaagattaca ggtacacgta ccgatgccat agaggtgaca cacaaataca aacccgaaga   1740tcatttgaaa taaagaaact gtgggagcaa acccgttcca aagctggact gctggtctcc   1800gacggaggcc caaatttata caacattaga aatctccaca ttcctgaagt ctgcctaaaa   1860tgggaattga tggatgagga ttaccagggg cgtttatgca acccactgaa cccatttgtc   1920agccataaag aaattgaatc aatgaacaat gcagtgatga tgccagcaca tggtccagcc   1980aaaaacatgg agtatgatgc tgttgcaaca acacactcct ggatccccaa aagaaatcga   2040tccatcttga atacaagtca aagaggagta cttgaggatg aacaaatgta ccaaaggtgc   2100tgcaatttat ttgaaaaatt cttccccagc agttcataca gaagaccagt cgggatatcc   2160agtatggtgg aggctatggt ttccagagcc cgaattgatg cacggattga tttcgaatct   2220ggaaggataa agaaagaaga gttcactgag atcatgaaga tctgttccac cattgaagag   2280ctcagacggc aaaaatagtg aatttagctt gtccttcatg aaaaaatgcc ttgtttctac   2340t                                                                   2341</s400><s200><s210>3</s210><s211>2341</s211><s212>DNA</s212><s213>Influenza PR8-X</s213></s200><s400> 3agcgaaagca ggtcaattat attcaatatg gaaagaataa aagaactaag aaatctaatg     60tcgcagtctc gcacccgcga gatactcaca aaaaccaccg tggaccatat ggccataatc    120aagaagtaca catcaggaag acaggagaag aacccagcac ttaggatgaa atggatgatg    180gcaatgaaat atccaattac agcagacaag aggataacgg aaatgattcc tgagagaaat    240gagcaaggac aaactttatg gagtaaaatg aatgatgccg gatcagaccg agtgatggta    300tcacctctgg ctgtgacatg gtggaatagg aatggaccaa taacaaatac agttcattat    360ccaaaaatct acaaaactta ttttgaaaga gtagaaaggc taaagcatgg aacctttggc    420cctgtccatt ttagaaacca agtcaaaata cgtcggagag ttgacataaa tcctggtcat    480gcagatctca gtgccaagga ggcacaggat gtaatcatgg aagttgtttt ccctaacgaa    540gtgggagcca ggatactaac atcggaatcg caactaacga taaccaaaga gaagaaagaa    600gaactccagg attgcaaaat ttctcctttg atggttgcat acatgttgga gagagaactg    660gtccgcaaaa cgagattcct cccagtggct ggtggaacaa gcagtgtgta cattgaagtg    720ttgcatttga ctcaaggaac atgctgggaa cagatgtata ctccaggagg ggaagtgagg    780aatgatgatg ttgatcaaag cttgattatt gctgctagga acatagtgag aagagctgca    840gtatcagcag atccactagc atctttattg gagatgtgcc acagcacaca gattggtgga    900attaggatgg tagacatcct taggcagaac ccaacagaag agcaagccgt ggatatatgc    960aaggctgcaa tgggactgag aattagctca tccttcagtt ttggtggatt cacatttaag   1020agaacaagcg gatcatcagt caagagagag gaagaggtgc ttacgggaaa tcttcaaaca   1080ttgaagataa gagtgcatga gggatatgaa gagttcacaa tggttgggag aagagcaaca   1140gccatactca gaaaagcaac caggagattg attcagctga tagtgagtgg gagagacgaa   1200cagtcgattg ccgaagcaat aattgtggcc atggtatttt cacaagagga ttgtatgata   1260aaagcagtca gaggtgatct gaatttcgtc aatagggcga atcagcgatt gaatcctatg   1320catcaacttt taagacattt tcagaaggat gcgagagtgc tttttcaaaa ttggggagtt   1380gaacctatcg acaatgtgat gggaatgatt gggatattgc ccgacatgac tccaagcatc   1440gagatgtcaa tgagaggagt gagaatcagc aaaatgggtg tagatgagta ctccagcacg   1500gagagggtag tggtgagcat tgaccgtttt ttgagaatcc gggaccaacg aggaaatgta   1560ctactgtctc ccgaggaggt cagtgaaaca cagggaacag agaaactgac aataacttac   1620tcatcgtcaa tgatgtggga gattaatggt cctgaatcag tattggtcaa tacctatcaa   1680tggatcatca gaaactggga aactgttaaa attcagtggt cccagaaccc tacaatgcta   1740tacaataaaa tggaatttga accatttcag tctttagtac ctaaggccat tagaggccaa   1800tacagtgggt ttgtaagaac tctgttccaa caaatgaggg atgtgcttgg gacatttgat   1860accgcacaga taataaaact tcttcccttc gcagccgctc caccaaagca aagtagaatg   1920cagttctcct catttactgt gaatgtgagg ggatcaggaa tgagaatact tgtaaggggc   1980aattctcctg tattcaacta taacaaggcc acgaagagac tcacagttct cggaaaggat   2040gctggcactt taactgaaga cccagatgaa ggcacagctg gagtggagtc cgctgttctg   2100aggggattcc tcattctggg caaagaagac aagagatatg ggccagcact aagcatcaat   2160gaactgagca accttgcgaa aggagagaag gctaatgtgc taattgggca aggagacgtg   2220gtgttggtaa tgaaacggaa acgggactct agcatactta ctgacagcca gacagcgacc   2280aaaagaattc ggatggccat caattagtgt cgaatagttt aaaaacgacc ttgtttctac   2340t                                                                   2341</s400><s200><s210>4</s210><s211>1565</s211><s212>DNA</s212><s213>Influenza PR8-X</s213></s200><s400> 4agcaaaagca gggtagataa tcactcactg agtgacatca aaatcatggc gtctcaaggc     60accaaacgat cttacgaaca gatggagact gatggagaac gccagaatgc cactgaaatc    120agagcatccg tcggaaaaat gattggtgga attggacgat tctacatcca aatgtgcacc    180gaactcaaac tcagtgatta tgagggacgg ttgatccaaa acagcttaac aatagagaga    240atggtgctct ctgcttttga cgaaaggaga aataaatacc ttgaagaaca tcccagtgcg    300ggaaaagatc ctaagaaaac tggaggacct atatacagga gagtaaacgg aaagtggatg    360agagaactca tcctttatga caaagaagaa ataaggcgaa tctggcgcca agctaataat    420ggtgacgatg caacggctgg tctgactcac atgatgatct ggcattccaa tttgaatgat    480gcaacttatc agaggacaag agctcttgtt cgcaccggaa tggatcccag gatgtgctct    540ctgatgcaag gttcaactct ccctaggagg tctggagccg caggtgctgc agtcaaagga    600gttggaacaa tggtgatgga attggtcaga atgatcaaac gtgggatcaa tgatcggaac    660ttctggaggg gtgagaatgg acgaaaaaca agaattgctt atgaaagaat gtgcaacatt    720ctcaaaggga aatttcaaac tgctgcacaa aaagcaatga tggatcaagt gagagagagc    780cggaacccag ggaatgctga gttcgaagat ctcacttttc tagcacggtc tgcactcata    840ttgagagggt cggttgctca caagtcctgc ctgcctgcct gtgtgtatgg acctgccgta    900gccagtgggt acgactttga aagggaggga tactctctag tcggaataga ccctttcaga    960ctgcttcaaa acagccaagt gtacagccta atcagaccaa atgagaatcc agcacacaag   1020agtcaactgg tgtggatggc atgccattct gccgcatttg aagatctaag agtattaagc   1080ttcatcaaag ggacgaaggt gctcccaaga gggaagcttt ccactagagg agttcaaatt   1140gcttccaatg aaaatatgga gactatggaa tcaagtacac ttgaactgag aagcaggtac   1200tgggccataa ggaccagaag tggaggaaac accaatcaac agagggcatc tgcgggccaa   1260atcagcatac aacctacgtt ctcagtacag agaaatctcc cttttgacag aacaaccatt   1320atggcagcat tcaatgggaa tacagagggg agaacatctg acatgaggac cgaaatcata   1380aggatgatgg aaagtgcaag accagaagat gtgtctttcc aggggcgggg agtcttcgag   1440ctctcggacg aaaaggcagc gagcccgatc gtgccttcct ttgacatgag taatgaagga   1500tcttatttct tcggagacaa tgcagaggag tacgacaatt aaagaaaaat acccttgttt   1560ctact                                                               1565</s400><s200><s210>5</s210><s211>1027</s211><s212>DNA</s212><s213>Influenza PR8-X</s213></s200><s400> 5agcaaaagca ggtagatatt gaaagatgag tcttctaacc gaggtcgaaa cgtacgtact     60ctctatcatc ccgtcaggcc ccctcaaagc cgagatcgca cagagacttg aagatgtctt    120tgcagggaag aacaccgatc ttgaggttct catggaatgg ctaaagacaa gaccaatcct    180gtcacctctg actaagggga ttttaggatt tgtgttcacg ctcaccgtgc ccagtgagcg    240aggactgcag cgtagacgct ttgtccaaaa tgcccttaat gggaacgggg atccaaataa    300catggacaaa gcagttaaac tgtataggaa gctcaagagg gagataacat tccatggggc    360caaagaaatc tcactcagtt attctgctgg tgcacttgcc agttgtatgg gcctcatata    420caacaggatg ggggctgtga ccactgaagt ggcatttggc ctggtatgtg caacctgtga    480acagattgct gactcccagc atcggtctca taggcaaatg gtgacaacaa ccaatccact    540aatcagacat gagaacagaa tggttttagc cagcactaca gctaaggcta tggagcaaat    600ggctggatcg agtgagcaag cagcagaggc catggaggtt gctagtcagg ctagacaaat    660ggtgcaagcg atgagaacca ttgggactca tcctagctcc agtgctggtc tgaaaaatga    720tcttcttgaa aatttgcagg cctatcagaa acgaatgggg gtgcagatgc aacggttcaa    780gtgatcctct cactattgcc gcaaatatca ttgggatctt gcacttgaca ttgtggattc    840ttgatcgtct ttttttcaaa tgcatttacc gtcgctttaa atacggactg aaaggagggc    900cttctacgga aggagtgcca aagtctatga gggaagaata tcgaaaggaa cagcagagtg    960ctgtggatgc tgacgatggt cattttgtca gcatagagct ggagtaaaaa actaccttgt   1020ttctact                                                             1027</s400><s200><s210>6</s210><s211>890</s211><s212>DNA</s212><s213>Influenza PR8-X</s213></s200><s400> 6agcaaaagca gggtgacaaa aacataatgg atccaaacac tgtgtcaagc tttcaggtag     60attgctttct ttggcatgtc cgcaaacgag ttgcagacca agaactaggt gatgccccat    120tccttgatcg gcttcgccga gatcagaaat ccctaagagg aaggggcagt actctcggtc    180tggacatcaa gacagccaca cgtgctggaa agcagatagt ggagcggatt ctgaaagaag    240aatccgatga ggcacttaaa atgaccatgg cctctgtacc tgcgtcgcgt tacctaactg    300acatgactct tgaggaaatg tcaagggact ggtccatgct catacccaag cagaaagtgg    360caggccctct ttgtatcaga atggaccagg cgatcatgga taagaacatc atactgaaag    420cgaacttcag tgtgattttt gaccggctgg agactctaat attgctaagg gctttcaccg    480aagagggagc aattgttggc gaaatttcac cattgccttc tcttccagga catactgctg    540aggatgtcaa aaatgcagtt ggagtcctca tcggaggact tgaatggaat gataacacag    600ttcgagtctc tgaaactcta cagagattcg cttggagaag cagtaatgag aatgggagac    660ctccactcac tccaaaacag aaacgagaaa tggcgggaac aattaggtca gaagtttgaa    720gaaataagat ggttgattga agaagtgaga cacaaactga agataacaga gaatagtttt    780gagcaaataa catttatgca agccttacat ctattgcttg aagtggagca agagataaga    840actttctcgt ttcagcttat ttagtactaa aaaacaccct tgtttctact               890</s400><s200><s210>7</s210><s211>1775</s211><s212>DNA</s212><s213>Influenza PR8-X</s213></s200><s400> 7agcaaaagca ggggaaaata aaaacaacca aaatgaaggc aaacctactg gtcctgttat     60gtgcacttgc agctgcagat gcagacacaa tatgtatagg ctaccatacg aacaattcaa    120ccgacactgt tgacacagta ctcgagaaga atgtgacagt gacacactct gttaacctgc    180tcgaagacag ccacaacgga aaactatgta gattaaaagg aatagcccca ctacaattgg    240ggaaatgtaa catcgccgga tggctcttgg gaaacccaga atgcgaccca ctgcttccag    300tgagatcatg gtcctacatt gtagaaacac caaactctga gaatggaata tgttatccag    360gagatttcat cgactatgag gagctgaggg agcaattgag ctcagtgtca tcattcgaaa    420gattcgaaat atttcccaaa gaaagctcat ggcccaacca caacacaaac ggagtaacgg    480cagcatgctc ccatgagggg aaaagcagtt tttacagaaa tttgctatgg ctgacggaga    540aggagggctc atacccaaag ctgaaaaatt cttatgtgaa caaaaaaggg aaagaagtcc    600ttgtactgtg gggtattcat cacccgccta acagtaagga acaacagaat ctctatcaga    660atgaaaatgc ttatgtctct gtagtgactt caaattataa caggagattt accccggaaa    720tagcagaaag acccaaagta agagatcaag ctgggaggat gaactattac tggaccttgc    780taaaacccgg agacacaata atatttgagg caaatggaaa tctaatagca ccaatgtatg    840ctttcgcact gagtagaggc tttgggtccg gcatcatcac ctcaaacgca tcaatgcatg    900agtgtaacac gaagtgtcaa acacccctgg gagctataaa cagcagtctc ccttaccaga    960atatacaccc agtcacaata ggagagtgcc caaaatacgt caggagtgcc aaattgagga   1020tggttacagg actaaggaac attccgtcca ttcaatccag aggtctattt ggagccattg   1080ccggttttat tgaaggggga tggactggaa tgatagatgg atggtatggt tatcatcatc   1140agaatgaaca gggatcaggc tatgcagcgg atcaaaaaag cacacaaaat gccattaacg   1200ggattacaaa caaggtgaac actgttatcg agaaaatgaa cattcaattc acagctgtgg   1260gtaaagaatt caacaaatta gaaaaaagga tggaaaattt aaataaaaaa gttgatgatg   1320gatttctgga catttggaca tataatgcag aattgttagt tctactggaa aatgaaagga   1380ctctggaatt ccatgactca aatgtgaaga atctgtatga gaaagtaaaa agccaattaa   1440agaataatgc caaagaaatc ggaaatggat gttttgagtt ctaccacaag tgtgacaatg   1500aatgcatgga aagtgtaaga aatgggactt atgattatcc caaatattca gaagagtcaa   1560agttgaacag ggaaaaggta gatggagtga aattggaatc aatggggatc tatcagattc   1620tggcgatcta ctcaactgtc gccagttcac tggtgctttt ggtctccctg ggggcaatca   1680gtttctggat gtgttctaat ggatctttgc agtgcagaat atgcatctga gattagaatt   1740tcagagatat gaggaaaaac acccttgttt ctact                              1775</s400><s200><s210>8</s210><s211>1413</s211><s212>DNA</s212><s213>Influenza PR8-X</s213></s200><s400> 8agcaaaagca ggggtttaaa atgaatccaa atcagaaaat aataaccatt ggatcaatct     60gtctggtagt cggactaatt agcctaatat tgcaaatagg gaatataatc tcaatatgga    120ttagccattc aattcaaact ggaagtcaaa accatactgg aatatgcaac caaaacatca    180ttacctataa aaatagcacc tgggtaaagg acacaacttc agtgatatta accggcaatt    240catctctttg tcccatccgt gggtgggcta tatacagcaa agacaatagc ataagaattg    300gttccaaagg agacgttttt gtcataagag agccctttat ttcatgttct cacttggaat    360gcaggacctt ttttctgacc caaggtgcct tactgaatga caagcattca agtgggactg    420ttaaggacag aagcccttat agggccttaa tgagctgccc tgtcggtgaa gctccgtccc    480cgtacaattc aagatttgaa tcggttgctt ggtcagcaag tgcatgtcat gatggcatgg    540gctggctaac aatcggaatt tcaggtccag ataatggagc agtggctgta ttaaaataca    600acggcataat aactgaaacc ataaaaagtt ggaggaagaa aatattgagg acacaagagt    660ctgaatgtgc ctgtgtaaat ggttcatgtt ttactataat gactgatggc ccgagtgatg    720ggctggcctc gtacaaaatt ttcaagatcg aaaaggggaa ggttactaaa tcaatagagt    780tgaatgcacc taattctcac tatgaggaat gttcctgtta ccctgatacc gacaaagtga    840tgtgtgtgtg cagagacaat tggcatggtt cgaaccggcc atgggtgtct ttcgatcaaa    900acctggatta tcaaatagga tacatctgca gtggggtttt cggtgacaac ccgcgtcccg    960aagatggaac aggcagctgt ggtccagtgt atgttgatgg agcaaacgga gtaaagggat   1020tttcatatag gtatggtaat ggtgtttgga taggaaggac caaaagtcac agttccagac   1080atgggtttga gatgatttgg gatcctaatg gatggacaga gactgatagt aagttctctg   1140tgaggcaaga tgttgtggca atgactgatt ggtcagggta tagcggaagt ttcgttcaac   1200atcctgagct gacagggcta gactgtatga ggccgtgctt ctgggttgaa ttaatcaggg   1260gacgacctaa agaaaaaaca atctggacta gtgcgagcag catttctttt tgtggcgtga   1320atagtgatac tgtagattgg tcttggccag acggtgctga gttgccattc agcattgaca   1380agtagtctgt tcaaaaaact ccttgtttct act                                1413</s400><s200><s210>9</s210><s211>2220</s211><s212>DNA</s212><s213>Influenza 105p30</s213></s200><s400> 9agcgaaagca ggtactgatt cgaaatggaa gattttgtgc gacaatgctt caatccgatg     60attgtcgagc ttgcggaaaa ggcaatgaaa gagtatggag aggacctgaa aatcgaaaca    120aacaaatttg cagcaatatg cacccacttg gaagtatgct tcatgtattc agattttcat    180ttcatcaatg agcaaggcga atcaataata gtagagcctg aggacccaaa tgcactttta    240aaacacagat ttgagataat agaggggcga gatcgtacaa tggcatggac agttgtaaac    300agtatttgca acaccacagg agctgagaaa ccaaagtttc tgccagatct gtatgattac    360aaagagaata ggttcatcga aattggagtg acaaggagag aagttcacat atactatctg    420gaaaaggcca acaaaattaa atctgagaag acacatattc acattttctc atttactggc    480gaagaaatgg ccacaaaggc cgattacact ctcgatgaag aaagcagggc tagaattaaa    540accagactat tcaccataag gcaagaaatg gcaagcagag gtctttggga ctcctttcgt    600cagtccgaaa gaggcgaaga gacaattgaa gaaaggtttg aaatcacagg gacaatgcgc    660aggctcgctg atcaaagcct tccgccgaac ttctcctgca ttgagaattt tagagcctat    720gtggatggat ttgaaccgaa cggctacatt gagggcaagc tttctcaaat gtccaaagaa    780gtaaatgcta aaattgagcc ttttttgaaa acaacacctc gaccaattag acttccgaat    840gggcctcctt gttttcagcg gtcaaaattc ctgctgatgg attctttaaa attaagcatt    900gaggatccaa atcatgaagg ggagggaata ccactatatg atgcaatcaa gtgtatgaga    960acattctttg gatggaaaga acccactgtt gtcaagccac acgagaaggg aataaatccg   1020aattatctgc tgtcgtggaa gcaggtgttg gaagagctgc aggacattga gagtgaggag   1080aagattccaa gaacaaaaaa catgaaaaaa acgagtcagt taaagtgggc acttggtgag   1140aacatggcac cagagaaggt ggattttgat gactgtaaag atataagcga tttgaagcaa   1200tatgatagtg acgaacctga attaaggtca ttttcaagtt ggatccagaa tgagttcaac   1260aaggcatgcg agctgaccga ttcaatctgg atagagctcg atgagattgg agaagatgtg   1320gccccgattg aacacattgc aagcatgaga agaaattact tcacagctga ggtgtcccat   1380tgcagagcca ctgaatatat aatgaaaggg gtatacatta atactgcttt gcttaatgca   1440tcctgtgcag caatggatga tttccaacta attcctatga taagcaaatg tagaactaaa   1500gagggaagga gaaagaccaa tttgtacggc ttcatcataa aaggaagatc tcacttaagg   1560aatgataccg atgtggtaaa ctttgtgagc atggagtttt ccctcactga cccaagactt   1620gagccacaca aatgggagaa gtactgtgtt cttgagatag gagatatgct tctaaggagt   1680gcaataggcc aagtgtcaag gcccatgttc ttgtatgtaa gaacaaatgg aacctcaaaa   1740attaaaatga aatggggaat ggagatgagg cgttgcctcc tccaatccct ccaacaaata   1800gagagcatga ttgaagctga gtcctctgtc aaggagaaag acatgacaaa agagtttttt   1860gagaatagat cagaaacatg gcccattgga gagtcaccaa aaggagtgga agaaggttcc   1920attgggaaag tatgcaggac actattggct aaatcagtat tcaatagtct gtatgcatct   1980ccacaattag aaggattttc agctgagtca agaaagttgc tccttattgt tcaggctctt   2040agggacaatc tggaacctgg gacctttgat cttgggggac tatatgaagc aattgaggag   2100tgcctgatta atgatccctg ggttttgctt aatgcttctt ggttcaactc cttcctaaaa   2160catgcattga gatagctgag gcaatgctac tatttgttat ccatactgtc caaaaaagta   2220</s400><s200><s210>10</s210><s211>2341</s211><s212>DNA</s212><s213>Influenza 105p30</s213></s200><s400> 10agcgaaagca ggcaaaccat ttgaatggat gtcaatccga cattactttt cttaaaagtg     60ccagcacaaa atgctataag cacaactttt ccttatactg gtgaccctcc ttacagccat    120ggaacaggaa caggatacac catggataca gtcaacagga cacatcagta ctcagaaaga    180ggaagatgga cgaaaaatac cgaaactgga gcaccgcaac tcaacccaat tgatgggcca    240ctaccagaag acaatgaacc aagtggctat gcccaaacag attgtgtatt agaggcaatg    300gctttccttg aagaatccca tcctggtatt tttgaaaact cttgtattga aacaatggag    360gttgttcagc aaacaagggt ggacaaactg acacaaggca gacaaaccta tgactggact    420ctaaatagga accagcctgc tgccacagca ttggcaaaca ccatagaagt attcagatca    480aatggcctca tagcaaatga atctggaagg ctaatagact tccttaaaga tgtaatggag    540tcgatggaca gagacgaagt agaggtcaca actcattttc aaagaaagag gagagtgaga    600gacaatgtaa ctaaaaaaat ggtgacccaa agaacaatag gaaaaaagaa acataaatta    660gacaaaagaa gttacctaat tagggcatta accctgaaca caatgaccaa agatgctgag    720agggggaaac taaaacgcag agcaattgca accccaggaa tgcaaataag ggggtttgta    780tactttgttg agacactggc aagaagcata tgtgaaaagc ttgaacaatc agggttgcca    840gttggaggaa atgagaagaa agcaaagtta gcaaatgttg taaggaagat gatgaccaac    900tcccaggaca ctgaaatttc ttttaccatc actggagata acacaaaatg gaacgaaaat    960caaaacccta gaatgttctt ggccatgatc acatatataa ccaaagatca gcctgaatgg   1020ttcagaaata ttctaagtat tgctccaata atgttttcaa acaaaatggc gagactaggt   1080agggggtata tgtttgaaag caagagtatg aaactgagaa cccaaatacc tgcagagatg   1140ctagccaaca tagatttgaa atatttcaat gattcaacta aaaagaaaat tgaaaaaatt   1200cgaccattat taatagatgg aactgcatca ttgagtcctg gaatgatgat gggcatgttc   1260aatatgttaa gcaccgtctt gggcgtttcc attctgaatc ttgggcaaaa aagatacacc   1320aagactactt actggtggga tggtcttcaa tcgtctgatg attttgcttt gattgtgaat   1380gcacccaatt atgcaggaat tcaagctgga gttgacaggt tttatcgaac ctgtaagctg   1440ctcggaatta atatgagcaa aaagaagtct tacataaaca gaacaggtac ctttgaattc   1500acgagctttt tctatcgtta tgggtttgtt gccaatttca gcatggagct tcctagtttt   1560ggggtgtctg gggtcaatga atctgcagac atgagtattg gagtcactgt catcaaaaac   1620aatatgataa acaatgacct tggcccagca actgctcaaa tggcccttca gttatttata   1680aaagattaca ggtacactta tcgatgccac agaggtgaca cacaaataca aacccggaga   1740tcatttgaaa taaagaaact atgggaccaa acccgctcca aagctgggct gttggtctct   1800gatggaggcc ccaatttata taacattagg aatctacata ttcctgaagt ctgcttgaaa   1860tgggagttga tggatgagga ttaccagggg cgtttatgca acccattgaa cccgtttgtc   1920agccataaag agattgaatc agtgaacaat gcagtgataa tgccggcaca tggtccagcc   1980aaaaatatgg agtatgacgc tgttgcaaca acacactctt gggtccccaa aagaaatcga   2040tccattttaa acacgagcca aagagggata cttgaagatg agcaaatgta ccaaaggtgc   2100tgcaatttat ttgaaaaatt cttcccaagt agctcataca gaagaccagt tggaatatcc   2160agtatggtag aggctatggt ttcaagagcc cgaattgatg cacggattga tttcgaatct   2220ggaaggataa agaaagagga attcgctgag atcatgaaga cctgttccac cattgaagac   2280ctcagacggc aaaaataggg aatttggctt gtccttcatg aaaaaatgcc ttgtttctac   2340t                                                                   2341</s400><s200><s210>11</s210><s211>2341</s211><s212>DNA</s212><s213>Influenza 105p30</s213></s200><s400> 11agcgaaagca ggtcaattat attcaatatg gaaagaataa aagagctaag gaatctgatg     60tcacaatctc gcactcgcga gatacttacc aaaactactg tagaccacat ggccataata    120aagaaataca catcaggaag acaggagaaa aacccatcac ttaggatgaa atggatgatg    180gcaatgaaat acccaattac agctgataaa aggataacgg aaatgattcc tgaaagaaat    240gagcaaggac agacactatg gagtaaagtg aatgatgccg gatcagaccg agtgatgata    300tcacccctag ctgtgacatg gtggaacaga aatggaccag tggcaaacac tatccactat    360ccaaaaatct acaaaactta ctttgaaaag gttgaaaggt taaaacatgg aacctttggc    420cctgtacact ttagaaacca agtcaaaata cgccgaagag tcgacataaa tcctggtcat    480gcagacctca gcgccaagga ggcacaggat gtaattatgg aagttgtttt ccctaatgaa    540gtgggagcca gaatactaac atcagaatcg caattaacga taactaagga gaaaaaagag    600gaactccaga attgcaaaat ttcccctttg atggttgcat acatgttaga gagggaactt    660gtccgcaaaa caagatttct cccggttgca ggtggaacaa gcagtgtgta cattgaagtt    720ttgcatttaa cacaggggac atgctgggag cagatgtaca ctccaggtgg ggaggtgagg    780aatgatgatg ttgatcaaag cctaattatt gctgctagga acatagtgag aagagctgca    840gtatcagcag atccactagc atctttatta gaaatgtgcc atagcacaca gattggtgga    900acaaggatgg tggatattct caggcaaaat ccaacagaag aacaagctgt ggacatatgc    960aaagcagcaa tggggctgag aatcagttca tccttcagtt ttggcggatt cacatttaag   1020agaacaagtg gatcgtcagt caaaagggag gaagaagtgc taacgggcaa tctgcaaaca   1080ttgaagctaa ctgtgcatga gggatatgaa gaattcacaa tagttgggaa aaaggcaaca   1140gctatactca gaaaagcaac caggagattg attcaactaa tagtgagtgg aagagacgaa   1200cagtcaatag tcgaagcaat agttgtagca atggtattct cacaagaaga ttgcatggta   1260aaagcggtta gaggtgatct gaatttcgtt aatagagcga atcagcggtt gaatcccatg   1320catcaacttt tgagacattt tcagaaggat gctaaagtac ttttcctaaa ttggggaatt   1380gaacatattg acaatgtgat gggaatgatt gggatattac ctgatatgac tccaagtacc   1440gagatgtcaa tgagaggagt gagagtcagc aaaatgggtg tagatgaata ctccaatgct   1500gaaagggtag tggtaagcat tgaccgtttt ttgagggtcc gggaccaaag aggaaatgta   1560ttactgtctc cagaggaagt cagtgaaaca caaggaacag agaaactgac aataacttac   1620tcttcatcat tgatgtggga gattaatggc cctgagtcag tgttgatcaa tacctaccaa   1680tggatcatca gaaactggga gactgttaaa attcagtggt ctcagaaccc tacaatgcta   1740tacaataaaa tggaatttga gccatttcaa tctctagtcc ccaaggccat tagaggccaa   1800tacagtgggt ttgttagaac tctatttcaa caaatgaggg atgtgctcgg gacctttgac   1860acaactcaga taataaaact tcttcccttt gcagccgctc caccaaagca aagtagaatg   1920caattctcgt cattaactgt gaatgtgagg ggatcaggaa tgagaatact tgtaaggggt   1980aattctccag tattcaacta caacaagacc actaagagac tcacaatcct cggaaaggat   2040gctggcactt taactgaaga cccagatgaa ggcacagctg gagtggaatc tgctgtttta   2100aggggattcc tcattctagg caaagaagat agaagatatg ggccagcatt aagcatcagt   2160gaattgagca accttgcgaa aggggagaaa gctaatgtgc taattgggca aggggatgta   2220gtgttggtaa tgaaacgaaa acgggactct agcatactta ctgacagcca gacagcgacc   2280aaaagaattc ggatggccat caattaattt cgaataattt aaaaacgacc ttgtttctac   2340t                                                                   2341</s400><s200><s210>12</s210><s211>1565</s211><s212>DNA</s212><s213>Influenza 105p30</s213></s200><s400> 12agcaaaagca gggtagataa tcactcactg agtgacatca aagtcatggc gtcccaaggc     60accaaacggt cttacgaaca gatggagact gatggggaac gccagaatgc aactgaaatc    120agagcatccg tcggaagaat gattggggga attgggcgat tctacatcca aatgtgcacc    180gagcttaagc tcaatgatta tgagggacga ctgatccaga acagcttaac aatagagaga    240atggtgcttt ctgcttttga tgagaggaga aataaatatc tggaagaaca tcccagcgca    300gggaaagatc ctaagaaaac tggaggaccc atatacaaga gagtagatgg aaagtgggtg    360agggaactcg tcctttatga caaagaagaa ataaggcgga tttggcgcca agccaacaat    420ggtgatgatg caacagctgg tttgactcac attatgatct ggcattctaa tttgaatgat    480acaacttacc agaggacaag agctcttgtc cgcaccggaa tggatcccag gatgtgctct    540ttgatgcaag gttcaactct ccctagaaga tctggagcag caggcgctgc agtcaaagga    600gttgggacaa tggtattgga gttaatcagg atgatcaaac gtgggatcaa cgaccgaaac    660ttctggaggg gtgagaatgg gagaaaaaca aggattgctt atgagagaat gtgcaacatt    720ctcaaaggaa aatttcaaac agctgcacaa aaagcaatga tggatcaagt gagagaaagc    780cggaacccag gaaatgctga gatcgaagat ctcacttttc tggcacggtc tgcactcata    840ttgagaggat cagttgctca caagtcttgc ctgcctgctt gtgtgtatgg accagccgta    900gccagtgggt atgacttcga aaaagaggga tactctttgg tgggagtaga ccctttcaaa    960ctgcttcaaa ccagtcaggt atacagccta attagaccaa acgagaatcc cgcacacaag   1020agccagttgg tgtggatggc atgcaattct gctgcatttg aagatctaag agtgtcaagc   1080ttcatcagag ggacaagagt acttccaagg gggaagctct ccactagagg agtacaaatt   1140gcttcaaatg aaaacatgga tgctattgtc tcaagtactc ttgaactgag aagcagatac   1200tgggccataa gaaccagaag tggagggaac accaatcaac aaagggcctc tgcgggccaa   1260atcagcacac aacctacgtt ttctgtgcag agaaacctcc catttgacaa aacaaccatc   1320atggcagcat tcactgggaa tacagaggga agaacatcag acatgcgggc agaaatcata   1380aagatgatgg aaagtgcaag accagaagaa gtgtccttcc agggacgggg agtctttgag   1440ctctcggacg aaagggcaac gaacccgatc gtgccctcct ttgacatgag taatgaagga   1500tcttatttct tcggagacaa tgcagaggag tacgacaatt aatgaaaaat acccttgttt   1560ctact                                                               1565</s400><s200><s210>13</s210><s211>1027</s211><s212>DNA</s212><s213>Influenza 105p30</s213></s200><s400> 13agcaaaagca ggtagatatt gaaagatgag tcttctaacc gaggtcgaaa cgtacgttct     60ctctatcgtc ccatcaggcc ccctcaaagc cgagatcgca cagagacttg aagatgtatt    120tgctggaaag aataccgatc ttgaggctct catggaatgg ctaaagacaa gaccaatcct    180gtcacctctg actaagggga ttttaggatt tgtgttcacg ctcaccgtgc ccagtgagcg    240aggactgcag cgtagacgct ttgtccaaaa tgcccttaat gggaatgggg atccaaataa    300tatggacaag gctgtcaaac tgtatcgaaa gcttaagagg gagataacat tccatggggc    360caaagaaata gcactcagtt attctgctgg agcacttgcc agttgtatgg gactcatata    420caacaggatg ggggctgtga ccaccgaatc agcatttggc cttatatgtg caacctgtga    480acagattgcc gactcccagc ataagtctca taggcaaatg gtaacaacaa ccaatccatt    540aataagacat gagaacagaa tggttctggc cagcactaca gctaaggcta tggagcaaat    600ggctggatcg agtgaacaag cagctgaggc catggaggtt gctagtcagg ccaggcagat    660ggtgcaggca atgagagcca ttgggactca tcctagctct agcactggtc tgaaaaatga    720tctccttgaa aatttgcagg cctatcagaa acgaatgggg gtgcagatgc aacgattcaa    780gtgatcctct tgttgttgcc gcaagtataa ttgggattgt gcacctgata ttgtggatta    840ttgatcgcct tttttccaaa agcatttatc gtatttttaa acacggttta aaaagagggc    900cttctacgga aggagtaccg gagtctatga gggaagaata tcgagaggaa cagcagaatg    960ctgtggatgc tgacgatggt cattttgtca gcatagagct agagtaaaaa actaccttgt   1020ttctact                                                             1027</s400><s200><s210>14</s210><s211>889</s211><s212>DNA</s212><s213>Influenza 105p30</s213></s200><s400> 14agcaaaagca gggtggcaaa gacataatgg attcccacac tgtgtcaagc tttcaggtag     60attgtttcct ttggcatgtc cgcaaacaag ttgcagacca agatctaggc gatgccccct    120tccttgatcg gcttcgccga gatcagaagt ctctaaaggg acgaggcaac actctcggtc    180tgaacatcga aacagccact tgtgttggaa agcaaatagt agagaggatt ctgaaagaag    240aatccgatga gacatttaga atgaccatgg cctccgcact tgcttcgcgg tacctaactg    300acatgactgt tgaagaaatg tcaagggact ggttcatgct catgcccaag cagaaagtgg    360ctggccctct ttgtgtcaga atggaccagg cgataatgga taagaacatc atactgaaag    420cgaacttcag tgtgattttt gaccggttgg agaatctgac attactaagg gctttcaccg    480aagagggagc aattgttggc gaaatttcac cattgccttc ttttccagga catactaatg    540aggatgtcaa aaatgcaatt ggggtcctca tcgggggact tgaatggaat gataacacag    600ttcgagtctc tgaagctcta cagagattcg cttggagaag cagtaatgag actgggggac    660ctccattcac tacaacacag aaacggaaaa tggcgggaac aattaggtca gaagtttgaa    720gaaataagat ggctgattga agaagtgagg cataaattga agacgacaga gagtagtttt    780gaacaaataa catttatgca agcattacag ctattgtttg aagtggaaca agagattaga    840acgttctcgt ttcagcttat ttaatgataa aaacaccctt gtttctact                889</s400><s200><s210>15</s210><s211>1775</s211><s212>DNA</s212><s213>Influenza 105p30</s213></s200><s400> 15agcgaaagca ggggaaaata aaagcaacca aaatgaaagt aaaactactg gttctgttat     60gtacatttac agctacatat gcagacacaa tatgtatagg ctaccatgcc aacaactcaa    120ccgacactgt tgacacagta cttgagaaga atgtaacagt gacacactct gtcaacctac    180ttgaggacag tcacaatgga aaactatgtc tactaaaagg aatagcccca ctacaattgg    240gtaattgcag cgttgccgga tggatcttag gaaacccaga atgcgaatta ctgatttcca    300aggaatcatg gtcctacatt gtagaaacac caaatcctga gaatggaaca tgttacccag    360ggtatttcgc cgactatgag gaactgaggg agcaattgag ttcagtatct tcatttgaaa    420ggttcgaaat attccccaaa gagagctcat ggcccaacca caccgtaacc ggagtatcag    480catcatgctc ccataacggg aaaagcagtt tttacagaaa tttgctatgg ctgacgggga    540agaatggttt gtacccaaac ctgagcaagt cctatgcaaa caacaaagag aaagaagtcc    600ttgtactatg gggtgttcat cacccgccta acatagggga ccaaagggcc ctctatcata    660cagaaaatgc ttatgtctct gtagtgtctt cacattatag cagaagattc accccagaaa    720tagccaaaag acccaaggtg agagaccagg aaggaagaat caactactac tggactctgc    780tggaacccgg ggatacaata atatttgagg caaatggaaa tctaatagcg ccaaggtatg    840ctttcgcact gagtagaggc ttgggatcag gaatcatcac ctcaaatgca ccaatggatg    900aatgtgatgc aaagtgtcaa acacctcagg gagctataaa cagcagtctt cctttccaga    960atgtacaccc agtcacaata ggagagtgtc caaagtatgt caggagtgca aaattaagga   1020tggttacagg actaaggaac atcccatcca ttcaatccag aggtttgttt ggagcaattg   1080ccggtttcat tgaagggggg tggactggaa tggtagatgg ttggtatggt tatcatcatc   1140agaatgagca aggatctggg tatgctgcag atcaaaaaag cacacaaaat gccattaacg   1200ggattacaaa caaggtgaat tctgtaattg agaaaatgaa cactcaattc acagctgtgg   1260gcaaagaatt caacaaattg gaaagaagga tggaaaactt aaataaaaaa gttgatgatg   1320ggtttctaga catttggacc tataatgcag aattgttggt tctactggaa aatgaaagga   1380ctttggattt ccatgactcc aacgtgaaga atctgtatga gaaagtaaaa agccaattaa   1440agaataatgc caaagaaata ggaaacgggt gttttgaatt ctatcacaag tgtaacgatg   1500aatgcatgga gagtgtgaaa aatggaactt atgactatcc aaaatattcc gaagaatcaa   1560agttaaacag agagaaaatt gatggagtga aattggaatc aatgggagtc tatcagattc   1620tggcgatcta ctcaacagtc gccagttccc tggttctttt ggtctccctg ggggcaatca   1680gcttctggat gtgttccaat gggtctttgc agtgtagaat atgcatctaa gaccagaatt   1740tcagaaatat aaggaaaaac acccttgttt ctact                              1775</s400><s200><s210>16</s210><s211>1462</s211><s212>DNA</s212><s213>Influenza 105p30</s213></s200><s400> 16agcaaaagca ggagtttaaa atgaatccaa atcaaaaaat aataaccatt ggatcaatca     60gtatagcaat cggaataatt agtctaatgt tgcaaatagg aaatattatt tcaatatggg    120ctagtcactc aatccaaact ggaagtcaaa accacactgg aatatgcaac caaaaaatca    180tcacatatga aaacagcacc tgggtgaatc acacatatgt taatattaac aacactaatg    240ttgttgctgg aaaggacaaa acttcagtga cactggccgg caattcatct ctttgtccta    300tcagtggatg ggctatatac acaaaagaca acagcataag aattggctcc aaaggagatg    360tttttgtcat aagagaacct ttcatatcat gttctcactt ggaatgcaga accttttttc    420tgacccaagg tgctctatta aatgacaaac attcaaatgg aaccgttaag gacagaagtc    480cttatagggc cttaatgagc tgtcctctag gtgaagcccc gtcaccatac aattcaaagt    540ttgaatcagt tgcatggtca gcaagcgcat gccatgatgg caagggctgg ttaacaatcg    600gaatttctgg tccagacaat ggagctgtgg ctgtactaaa atacaacgga ataataactg    660aaaccataaa aagttgggaa aagcgaatat tgagaacaca agagtctgaa tgtgtttgtg    720tgaacgggtc atgtttcacc ataatgaccg atggcccgag taatggggcc gcctcgtaca    780aaatcttcaa gatcgaaaag gggaaggtta ctaaatcaac agagttgaat gcacccaatt    840ttcattatga ggaatgttcc tgttacccag acactggcac agtgatgtgt gtatgcaggg    900acaactggca tggttcaaat cgaccttggg tatcttttaa tcaaaacttg gattatcaaa    960taggatacat ctgcagtgga gtgttcggtg acaatccgcg tcccaaagat gggaagggca   1020gctgtaatcc agtgactgtt gatggagcag acggagttaa ggggttttca tacaaatatg   1080gtaatggtgt ttggatagga aggactaaaa gtaacagact tagaaagggg tttgagatga   1140tttgggatcc taatggatgg acagataccg acagtgattt ctcagtgaaa caggatgttg   1200tggcaataac tgattggtca gggtacagcg gaagtttcgt ccaacatcct gagttaacag   1260gattggactg tataagacct tgcttctggg ttgagttagt cagaggactg cctagagaaa   1320atacaacaat ctggactagt gggagcagca tttctttttg tggcgttgat agtgatactg   1380caaattggtc ttggccagac ggtgctgagt tgccgttcac cattgacaag tagctcgttg   1440aaaaaaactc cttgtttcta ct                                            1462</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000972A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000972</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17779811</doc-number><date>20201201</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>15</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>N</subclass><main-group>7</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>10</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>31</main-group><subgroup>14</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>39</main-group><subgroup>15</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>7</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>10</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>31</main-group><subgroup>14</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2720</main-group><subgroup>12021</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2720</main-group><subgroup>12034</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>N</subclass><main-group>2720</main-group><subgroup>12064</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>2039</main-group><subgroup>5254</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">ATTENUATED AVIAN REOVIRUS STRAINS 94826 C140 AND 97139 C140</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>62942426</doc-number><date>20191202</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.</orgname><address><city>Athens</city><state>GA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>SELLERS</last-name><first-name>Holly S.</first-name><address><city>Athens</city><state>GA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/US2020/062651</doc-number><date>20201201</date></document-id><us-371c12-date><date>20220525</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Attenuated isolates of avian reoviruses associated viral arthritis/tenosynovitis in poultry are presented, including avian reovims strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077 and progeny or derivatives thereof and avian reovims strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078 and progeny or derivatives thereof. Compositions and methods for administering the isolates or compositions as vaccines to control of reovims-induced viral arthritis/tenosynovitis in birds of the order Galliformes are also presented.</p></abstract><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">CONTINUING APPLICATION DATA</heading><p id="p-0002" num="0001">This application claims the benefit of U.S. Provisional Application Ser. No. 62/942,426, filed Dec. 2, 2019, which is incorporated by reference herein.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">BACKGROUND</heading><p id="p-0003" num="0002">Avian reoviruses are associated with several diseases in poultry, including malabsorption syndrome and runting and stunting syndrome (RSS), although their role as primary pathogens in these clinical syndromes is not clear. In contrast, the association of avian reoviruses with clinical cases of viral arthritis/tenosynovitis is quite clear, as reoviruses have been isolated from the tendons of affected birds. The control of reovirus-induced viral arthritis/tenosynovitis can be achieved by vaccination of broiler breeders with a combination of live and/or inactivated vaccines with maternal immunity passed on to progeny for early protection against field challenge. In broilers, live attenuated vaccines are available for use at day-of-hatch and for use in ovo. Current commercial vaccine strains (S1133, 1733, 2408, and 2177 to name a few) were isolated in the 1960-1970s and do not provide protection against currently circulating reovirus isolates from confirmed cases of viral arthritis/tenosynovitis. Thus, there is a need for the isolation and characterization of currently circulating avian reoviruses and the development of effective vaccines.</p><heading id="h-0003" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0004" num="0003">The present invention includes an isolated avian reovirus, wherein the isolated avian reovirus is the avian reovirus strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077, or a progeny or derivative thereof, wherein a progeny or derivative thereof has essentially the same biological and serological characteristics of the avian reovirus strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077.</p><p id="p-0005" num="0004">The present invention includes an isolated avian reovirus, wherein the isolated avian reovirus is the avian reovirus strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078, or a progeny or derivative thereof, wherein a progeny or derivative thereof has essentially the same biological and serological characteristics of the avian reovirus strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078.</p><p id="p-0006" num="0005">In some aspects, the present invention includes a Master Seed virus preparation of an avian reovirus as described herein.</p><p id="p-0007" num="0006">In some aspects, the isolated avian reovirus is lyophilized, freeze dried, frozen, or an effervescent tablet.</p><p id="p-0008" num="0007">In some embodiments, the present invention includes a composition including an isolated avian reovirus as described herein. In some aspects, a composition includes an adjuvant. In some aspects, a composition includes a pharmaceutically acceptable carrier. In some aspects, the composition is formulated for intranasal, intraocular, oral, mucosal, intramuscular, subcutaneous, or in ovo administration. In some aspects, the composition is formulated for spraying or aerolizing.</p><p id="p-0009" num="0008">In some embodiments, the present invention includes a vaccine including an isolated avian reovirus as described herein or a composition as described herein. In some aspects, the vaccine reduces the susceptibility of a bird of the order Galliformes to reovirus-induced viral arthritis/tenosynovitis. In some aspects, the reovirus-induced viral arthritis/tenosynovitis is a variant group 1/genotype 5-induced viral arthritis/tenosynovitis. In some aspects, the reovirus-induced viral arthritis/tenosynovitis is a variant group 2/genotype 1-induced viral arthritis/tenosynovitis.</p><p id="p-0010" num="0009">In some embodiments, the present invention includes a vaccine for birds of the order Galliformes comprising an amount of the avian reovirus strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077, or a progeny or derivative thereof, sufficient to protect the birds from reovirus-induced viral arthritis/tenosynovitis, and a pharmaceutically acceptable carrier. In some aspects, the reovirus-induced viral arthritis/tenosynovitis is a variant group 1/genotype 5-induced viral arthritis/tenosynovitis.</p><p id="p-0011" num="0010">In some embodiments, the present invention includes a vaccine for birds of the order Galliformes comprising an amount of the avian reovirus strain avian reovirus strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078, or a progeny or derivative thereof, sufficient to protect the birds from reovirus-induced viral arthritis/tenosynovitis, and a pharmaceutically acceptable carrier. In some aspects, the reovirus-induced viral arthritis/tenosynovitis is a variant group 2/genotype 1-induced viral arthritis/tenosynovitis.</p><p id="p-0012" num="0011">In some embodiments, the present invention includes an effervescent tablet comprising an avian reovirus, composition, or vaccine as described herein.</p><p id="p-0013" num="0012">The present invention includes a method for reducing susceptibility of a bird of the order Galliformes against reovirus-induced viral arthritis/tenosynovitis, the method comprising administering to the bird an avian reovirus, composition, or vaccine as described herein.</p><p id="p-0014" num="0013">The present invention includes a method for protecting a bird of the order Galliformes against reovirus-induced viral arthritis/tenosynovitis, the method comprising administering to the bird an avian reovirus, composition, or vaccine as described herein.</p><p id="p-0015" num="0014">In some aspects of the methods described herein, the reovirus-induced viral arthritis/tenosynovitis is a variant group 1/genotype 5-induced viral arthritis/tenosynovitis. In some aspects, the reovirus-induced viral arthritis/tenosynovitis is a variant group 2/genotype 1-induced viral arthritis/tenosynovitis. In some aspects, of the methods described herein, administration is intranasal, intraocular, oral, mucosal, intramuscular, or subcutaneous. In some aspects, of the methods described herein, administration includes in ovo administration. In some aspects, of the methods described herein, the avian reovirus, composition, or vaccine is administered by aerosol. In some aspects, of the methods described herein, the avian reovirus, composition, or vaccine is administered by drinking water. In some aspects, the bird is a chicken or turkey. In some aspects, of the methods described herein, administration is to a breeder hen or a rooster.</p><p id="p-0016" num="0015">The present invention includes a of producing anti-reovirus antibodies in poultry, the method comprising administering an isolated avian reovirus, composition, or vaccine as described herein to the bird. In some aspects, the bird is a chicken or turkey.</p><p id="p-0017" num="0016">The present invention includes a diagnostic kit including an isolated avian reovirus as described herein.</p><p id="p-0018" num="0017">The present invention includes a method of detecting exposure to an avian reovirus in a bird, the method comprising determining that an antisera sample obtained from the bird specifically binds to an avian reovirus as described herein. In some aspects, the bird is a chicken or turkey.</p><p id="p-0019" num="0018">The present invention includes a hyperimmune sera to an avian reovirus as described herein.</p><p id="p-0020" num="0019">The present invention includes an antibody that binds to an avian reovirus as described herein and does not bind to avian reovirus strain S1133, 1733, 2408, and/or 2177. In some aspects, the antibody is a monoclonal antibody.</p><p id="p-0021" num="0020">The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. In several places throughout the application, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0004" level="1">DETAILED DESCRIPTION</heading><p id="p-0022" num="0021">The present invention provides two attenuated avian reovirus strains, avian reovirus strain 94826 C140 and avian reovirus strain 96139 C140, and progeny, and derivatives thereof. These attenuated reovirus strains are safe and efficacious when administered to birds as live formulations in preventing avian reovirus infections and reducing the incidence and severity of reovirus-induced viral arthritis and/or tenosynovitis.</p><p id="p-0023" num="0022">In one aspect, the present invention includes avian reovirus strain 94826 C140 and progeny and derivatives thereof. Avian reovirus strain 94826 C140 is an attenuation of the avian reovirus strain 94826, obtained by passaging the avian reovirus strain 94826 one hundred forty times in chicken embryos. Avian reovirus strain 94816 is a Group 1/Genotype 5 reovirus associated with viral arthritis and tenosynovitis in poultry. Avian reovirus strain 94816 is described in more detail in International Application No. PCT/US2015/013449 (WO 2015/116778) and U.S. patent application Ser. No. 15/223,623, which are hereby incorporated by reference in their entireties. Attenuated avian reovirus strain 94826 C140 is also a Group 1/Genotype 5 avian reovirus. Attenuated avian reovirus strain 94826 C140 was deposited with the American Type Culture Collection (ATCC&#xae;), 10801 University Boulevard, Manassas, Va. 20110-2209, USA, under Patent Deposit Designation as PTA-126077 on Aug. 13, 2019. This deposit was in accordance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. Attenuated avian reovirus 94826 C140 is also archived as PDRC ref: 121116 in the virus repository at the Poultry Diagnostic and Research Center (PDRC) at the University of Georgia, located at 953 College Station Road Athens Ga., 20602. The safety and efficacy of avian reovirus strain 94826 C140 as a live, attenuated reovirus vaccine is described in more detail in Example 3.</p><p id="p-0024" num="0023">In another aspect, the present invention includes avian reovirus strain 96139 C140 and progeny and derivatives thereof. Avian reovirus strain 96139 C140 is an attenuation of avian reovirus strain 96139, obtained by passaging the avian reovirus strain 96139 one hundred forty times in chicken embryos. Avian reovirus strain 96139 is a Group 2/Genotype 1 avian reovirus associated with viral arthritis and tenosynovitis in poultry. Avian reovirus strain 96139 is described in more detail in International Application No. PCT/US2015/013449 (WO 2015/116778) and U.S. patent application Ser. No. 15/223,623, which are hereby incorporated by reference in their entireties. Avian reovirus strain 96139 was deposited with the ATCC&#xae; under Patent Deposit Designation as PTA-125688 on Mar. 7, 2019. Attenuated avian reovirus 96139 C140 is also a Group 2/Genotype 1 avian reovirus. Attenuated avian reovirus 96139 C140 was deposited with the American Type Culture Collection)(ATCC&#xae;, 10801 University Boulevard, Manassas, Va. 20110-2209, USA, under Patent Deposit Designation as PTA-126078 on Aug. 13, 2019. This deposit was in accordance with the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. Attenuated avian reovirus 9619 C140 is also archived as PDRC ref: 119812 in the virus repository at the Poultry Diagnostic and Research Center (PDRC) at the University of Georgia, located at 953 College Station Road Athens Ga., 20602. The safety and efficacy of avian reovirus strain 96139 C140 as a live, attenuated reovirus vaccine is described in more detail in Example 3.</p><p id="p-0025" num="0024">As discussed in more detail in International Application No. PCT/US2015/013449 (WO 2015/116778) and U.S. patent application Ser. No. 15/223,623, avian reovirus strains 94826 and 96139 represent two genetically and serologically distinct groups of avian reoviruses that have been isolated from clinical cases of tenosynovitis. Genetic analysis of their avian reovirus sigma C proteins reveals novel genotypes unrelated to current avian reovirus vaccine strains.</p><p id="p-0026" num="0025">Avian reoviruses, along with mammalian reoviruses, comprise the genus Orthoreovirus in the family Reoviridae. These viruses contain 10 dsRNA genome segments enclosed within a non-enveloped, icosahedral double capsid of approximately 80 nm. The genome segments can be separated based on electrophoretic mobility into three large (L1, L2, L3), three medium (M1, M2, M3) and four small (S1, S2, S3, S4) segments which code for proteins &#x3bb;1, &#x3bb;2, &#x3bb;3, &#x3bc;1, &#x3bc;2, &#x3bc;NS, &#x3c3;3, &#x3c3;1, &#x3c3;2, &#x3c3;NS, respectively. The &#x3c3;2 protein is an outer capsid protein which carries group-specific neutralizing epitopes. It also binds double-stranded RNA and has been identified as a zinc metalloprotein. The sigma C protein, the minor outer capsid protein encoded by the &#x3c3;1 segment, is the target for molecular characterization of avian reoviruses and is responsible for cell attachment, as well as induction of type-specific neutralizing antibodies. An avian reovirus virion includes a capsid, a core, and a nucleoprotein complex. The virus capsid is not enveloped. The capsid/nucleocapsid is isometric with icosahedral symmetry and has a diameter of about 80-82 nm. The capsid shells of virions are composed of two layers. All shells are usually present, or the outer shell is often lost during preparation. Capsids appear round. The capsid surface structure reveals a regular pattern with distinctive features. The capsomer arrangement is clearly visible. Surface projections are not present. Inner capsids core has a diameter of about 60 nm. Virus preparations contain one particle component. The core is spherical and consists of the dsRNA genome with a diameter of about 49 nm. The ends of the fibers protrude almost through to the capsid surface.</p><p id="p-0027" num="0026">The present invention includes Master Seed virus preparations prepared from avian reovirus strain 94826 C140 (deposited with the ATCC&#xae; under Patent Deposit Designation as PTA-126077 on Aug. 13, 2019) or avian reovirus strain 96139 C140 (deposited with the ATCC&#xae; under Patent Deposit Designation as PTA-126078 on Aug. 13, 2019). Master Seed virus preparation of the present invention may be prepared and tested according to Title 9 of the Code of Federal Regulations (CFR) &#xa7; 113.332 (Tenosynovitis Vaccine).</p><p id="p-0028" num="0027">Also included in the present invention are isolated progeny and isolated derivatives of avian reovirus strain 94826 C140 (deposited with the ATCC&#xae; under Patent Deposit Designation as PTA-126077 on Aug. 13, 2019) and avian reovirus strain 96139 C140 (deposited with the ATCC&#xae; under Patent Deposit Designation as PTA-126078 on Aug. 13, 2019) with equivalent or similar biological, serological, and/or genetic characteristics. As used herein, serological, biological, and genetic characteristics may include one or more of the characteristics described in the data in the Examples included herewith. More particularly, progeny or derivative strains of PTA-126077 or PTA-1260789495 may retain the particularly favorable protective properties belonging to the present invention, as described in more detail in the examples included herewith.</p><p id="p-0029" num="0028">Avian reovirus according to the invention can be propagated by conventional methods, including, but not limited to, any of those described in the examples section included herewith. In brief, a substrate able to support the replication of an avian reovirus is inoculated with an avian reovirus of the present invention and propagated until the virus is replicated to a desired infectious titer, or antigen mass content. Reovirus containing material is then harvested. Suitable substrates may include embryonated eggs, primary (avian) cell cultures, such as, for example, chicken embryo liver cells, chicken embryo fibroblasts, or chicken kidney cells, mammalian cell lines, such as, for example, the VERO cell line or the BGM-70 cell line, or avian cell lines, such as, for example, QT-35, QM-7 or LMH.</p><p id="p-0030" num="0029">The present invention includes compositions and vaccines including one or more of the isolated viruses described herein. Vaccine preparations of the present invention may be prepared and tested according to Title 9 of the Code of Federal Regulations (CFR) &#xa7; 113.332 (Tenosynovitis Vaccine).</p><p id="p-0031" num="0030">In some embodiments, the virus is live. In some embodiments, the virus is inactivated or killed. In some embodiments, a virus or composition or vaccine thereof may be lyophilized. In some embodiments, a virus or composition or vaccine thereof may be frozen. In some embodiments, a virus or composition or vaccine thereof may be freeze dried.</p><p id="p-0032" num="0031">In some embodiments, a virus or composition or vaccine thereof may be formulated as an effervescent table. Such effervescent tablets may, for example, be packaged in lightweight aluminum blisters. The table may be dissolved in water and administered, for example, orally, nasally, or by aerosol spray, whereby droplets enter via the mucus membranes of the birds.</p><p id="p-0033" num="0032">Such a compositions and vaccine may be administered as the active component to immunize a bird to elicit an immune response to a group 1 and/or group 2 avian reovirus and/or induce immunity against such an avian reovirus. Immunity may include the induction of a higher level of protection in a population of birds after vaccination compared to an unvaccinated group. The immune response may, or may not, confer protective immunity. An immune response may, for example, include one or more of a cell mediated immune response, which involves the production of lymphocytes in response to exposure to the antigen and/or a humoral immune response, which involves production of plasma lymphocytes (B cells) in response to antigen exposure with subsequent antibody production. Immunization may result in the reduction, inhibition, or prevention of one or more of the symptoms of avian reovirus associated viral arthritis (VA)/tenosynovitis. Such symptoms may include one or more of body weight suppression, decrease in egg production, mortality, macroscopic lesions (including, but not limited to tendon swelling, tenosynovitis, tendon rupture, and hydropericardium), and histological changes (including, but not limited to lymphocytic tenosynovitis, lymphocytic epicarditis, and lymphocytic myocarditis).</p><p id="p-0034" num="0033">A composition or vaccine of the present invention may also include one or more compounds with adjuvant activity. Suitable compounds or compositions for this purpose include aluminum hydroxide, aluminum phosphate, aluminum oxide, plant oils, animal oils, oil-in-water or water-in-oil emulsion based on, for example a mineral oil, such as Bayol F&#x2122; or Marcol 52&#x2122;, Complete Freund's adjuvant, incomplete Freund's adjuvant, or a vegetable oil such as vitamin E acetate, and saponins.</p><p id="p-0035" num="0034">A composition or vaccine of the present invention may include one or more suitable pharmaceutically acceptable carriers or diluents. An immunogenic composition or vaccine of the present invention may also contain one or more stabilizers. Any suitable stabilizer can be used including carbohydrates such as sorbitol, mannitol, starch, sucrose, dextrin, or glucose; proteins such as albumin or casein; and buffers such as alkaline metal phosphate and the like. A stabilizer is particularly advantageous when a dry vaccine preparation is prepared by lyophilization.</p><p id="p-0036" num="0035">A composition or vaccine of the present invention may further include one or more immunogens derived from other pathogens infectious to poultry. Such immunogens may be derived from, for example, Marek's disease virus (MDV), infectious bronchitis virus (IBV), Newcastle disease virus (NDV), egg drop syndrome (EDS) virus, turkey rhinotracheitis virus (TRTV), poxvirus, reovirus, chicken parvovirus, and avian nephritis virus (including, but not limited to ANV-1 and ANV-2).</p><p id="p-0037" num="0036">A composition or vaccine of the present invention may be administered by any suitable known method of inoculating poultry including nasally, ophthalmically, by injection, in drinking water, in the feed, by exposure, in ovo, maternally, by respiratory inhalation, and the like. The immunogenic composition or vaccine may be administered by mass administration techniques such as by placing the vaccine in drinking water or by spraying or aerolizing. When administered by injection, the immunogenic composition or vaccine may be administered parenterally. Parenteral administration includes, for example, administration by intravenous, subcutaneous, intramuscular, or intraperitoneal injection.</p><p id="p-0038" num="0037">In some embodiments, a live vaccine may be administered in a dose of not less than 10<sup>2 </sup>titration units (wherein titration units are defined in Title 9, Section 113.332, Code of Federal Regulations) per bird, and a vaccine may contain the antigenic equivalent of 10<sup>4</sup>-10<sup>10 </sup>TCID<sub>50 </sub>per bird (wherein TCID is an abbreviation for Tissue Culture Infective Dose).</p><p id="p-0039" num="0038">In some embodiments, a live vaccine may be administered in a dose of about 10<sup>1.5 </sup>to about 10<sup>7 </sup>TCID or EID (embryo infective does).</p><p id="p-0040" num="0039">In some aspects, a vaccine may contain the antigenic equivalent of about 10<sup>1.5 </sup>TCID<sub>50 </sub>per bird, about 10<sup>2 </sup>TCID<sub>50 </sub>per bird, about 10<sup>3 </sup>TCID<sub>50 </sub>per bird, about 10<sup>4 </sup>TCID<sub>50 </sub>per bird, about 10<sup>5 </sup>TCID<sub>50 </sub>per bird, about 10<sup>6 </sup>TCID<sub>50 </sub>per bird, about 10<sup>7 </sup>TCID<sub>50 </sub>per bird, about 10<sup>8 </sup>TCID<sub>50 </sub>per bird, about 10<sup>9 </sup>TCID<sub>50 </sub>per bird, about 10<sup>10 </sup>TCID<sub>50 </sub>per bird, or any range thereof.</p><p id="p-0041" num="0040">Compositions and vaccines of the present invention may be substantially pure. As used herein, &#x201c;substantially pure&#x201d; will mean material essentially free of any similar macromolecules or other biological entities that would normally be found with it in nature.</p><p id="p-0042" num="0041">Compositions and vaccines of the present invention may be administered to birds of any of a variety of avian species that are susceptible to infection with an avian reovirus, including, but not limited to, poultry, birds of the order Galliformes, and exotic bird species. Birds of the order Galliformes include, but are not limited to, chickens, turkeys, grouse, quails, and pheasants. As used herein, poultry includes domesticated birds that are kept for the purpose of collecting their eggs or killing for their meat and/or feathers. These most typically are members of the superorder Galloanserae (fowl), especially the order Galliformes (which includes, for example, chickens, quail, turkeys, and grouse) and the family Anatidae (in order Anseriformes), commonly known as &#x201c;waterfowl&#x201d; (including, for example, ducks, geese, and swans). Poultry may also include other birds which are killed for their meat, such as pigeons or doves or birds considered to be game, like pheasants. Chickens include, but are not limited to, hens, roosters, broilers, roasters, layers, breeders, the offspring of breeder hens, and layers. As used herein, the term &#x201c;susceptible to&#x201d; means the possibility or actuality of a detrimental response to the referenced microorganism, when compared to a non-susceptible individuals or groups, and/or one or more pathological state(s) indicative of avian reovirus infection.</p><p id="p-0043" num="0042">The vaccine of the present invention may be administered to poultry before or after hatching. Poultry may receive a vaccine at a variety of ages. For example, broilers may be vaccinated in ovo, at one-day-old, or at 2-3 weeks of age. Laying stock or reproduction stock may be vaccinated, for example, at about 6-12 weeks of age and boosted at about 16-20 weeks of age. Such laying stock or reproduction stock may be vaccinated at about 6, at about 7, at about 8, at about 9, at about 10, at about 11, or at about 12 weeks of age. Also, in some embodiments, such laying stock or reproduction stock may be vaccinated within about the first two weeks of age. Such laying stock or reproduction stock may be boosted at about 16, at about 17, at about 18, at about 19, or at about 20 weeks of age. The offspring of such laying stock or reproduction stock may demonstrate an antibody titer to a polypeptide as described herein, which may prevent or mitigate the symptoms of an avian reovirus infection in the offspring. In ovo vaccination may take place, for example, at about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, or at any range thereof.</p><p id="p-0044" num="0043">Chickens may be vaccinated at any suitable age and are usually about one to three days old before first vaccination. The chickens may be vaccinated only once. Or, if two doses of vaccine are used, the first is given, for example, when the chickens are 3 days to a week old and subsequently after a further 1-10 weeks.</p><p id="p-0045" num="0044">Multiple doses of the composition can be administered throughout the life of the chicken. As maternal immunity is a primary source of providing protection to broiler progeny, breeder chickens are typically vaccinated, although broiler chickens can be vaccinated if so desired.</p><p id="p-0046" num="0045">The present invention includes a method of producing an anti-variant group 1 and/or variant group 2 avian reovirus immune response in poultry, the method including administering an isolated virus, composition or vaccine as described herein. In some aspects, immunity includes humoral and/or cellular immunity. In some aspects, immunity includes mucosal immunity.</p><p id="p-0047" num="0046">The present invention includes a method of preventing an avian reovirus infection in poultry, the method including administering an isolated virus, composition or vaccine as described herein.</p><p id="p-0048" num="0047">In some aspects of the methods of the present invention, administration includes injection, spraying, oral administration, or respiratory administration. In some aspects of the methods of the present invention, administration induces mucosal immunity. In some aspects of the methods of the present invention, administration includes in ovo administration. In some aspects, in ovo administration includes administration at about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20 days, or any range thereof.</p><p id="p-0049" num="0048">The present invention includes a method of detecting exposure to a variant group 1 and/or a variant group 2 avian reovirus in a bird, the method including a determination of whether or not an antisera sample obtained from the bird specifically binds to a virus of the present invention. For example, the present invention includes the use of one or more avian reoviruses of the present invention in methods of detecting exposure to an avian reovirus in a bird, the method including determining that an antisera sample obtained from the bird specifically binds to an avian reovirus of the present invention.</p><p id="p-0050" num="0049">The present invention also includes kits including one or more of the avian reoviruses of the present invention. The kit may include one or more containers filled with an avian reovirus of the present invention. In some aspects, the virus may be, for example, lyophilized, freeze dried, frozen, or formulated as an effervescent tablet. The kit may include additional, separate containers of other strains of avian reoviruses or other pathogens of poultry. Such a kit may include additional components, such as for example, a positive control virus, a negative control virus, a secondary antibody, and/or a detectable marker. Additionally, the kit may include other reagents such as buffers and solutions needed to practice the invention are also included. Optionally associated with such container(s) can be a notice or printed instructions. A kit of the present invention may include &#x201c;packaging material.&#x201d; As used herein, the term &#x201c;packaging material&#x201d; refers to one or more physical structures used to house the contents of the kit. Packaging material is constructed by well known methods, preferably to provide a sterile, contaminant-free environment. Packaging material may be a solid matrix or a material such as glass, plastic, paper, foil, and the like.</p><p id="p-0051" num="0050">The present invention provides methods for detecting and/or measuring the amount of a group 1 or group 2 avian reovirus in a sample obtained from a bird. Such a method may include contacting a sample with an antibody that selectively binds to an avian reovirus as described herein as described herein and measuring the amount of binding of the antibody to a virus or protein in the sample. The sample may be any biological material, such as tissue, bone, blood, urine or faeces. The methods of this aspect of the invention are useful, for example, for determining whether poultry are infected with an avian reovirus of the present invention. Infected animals so identified can then be isolated or killed in order to prevent spread of the reovirus to other animals.</p><p id="p-0052" num="0051">As used herein, &#x201c;isolated&#x201d; refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered &#x201c;by the hand of man&#x201d; from its natural state.</p><p id="p-0053" num="0052">The term &#x201c;and/or&#x201d; means one or all of the listed elements or a combination of any two or more of the listed elements.</p><p id="p-0054" num="0053">The words &#x201c;preferred&#x201d; and &#x201c;preferably&#x201d; refer to embodiments of the invention that may afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful and is not intended to exclude other embodiments from the scope of the invention.</p><p id="p-0055" num="0054">The terms &#x201c;comprises&#x201d; and variations thereof do not have a limiting meaning where these terms appear in the description and claims.</p><p id="p-0056" num="0055">Unless otherwise specified, &#x201c;a,&#x201d; &#x201c;an,&#x201d; &#x201c;the,&#x201d; and &#x201c;at least one&#x201d; are used interchangeably and mean one or more than one.</p><p id="p-0057" num="0056">Also, herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).</p><p id="p-0058" num="0057">For any method disclosed herein that includes discrete steps, the steps may be conducted in any feasible order. And, as appropriate, any combination of two or more steps may be conducted simultaneously.</p><p id="p-0059" num="0058">Unless otherwise indicated, all numbers expressing quantities of components, molecular weights, and so forth used in the specification and claims are to be understood as being modified in all instances by the term &#x201c;about.&#x201d; Accordingly, unless otherwise indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.</p><p id="p-0060" num="0059">Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. All numerical values, however, inherently contain a range necessarily resulting from the standard deviation found in their respective testing measurements.</p><p id="p-0061" num="0060">In several places throughout the application, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.</p><p id="p-0062" num="0061">All headings are for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading, unless so specified.</p><p id="p-0063" num="0062">The invention is defined in the claims. However, below is provided a non-exhaustive list of non-limiting embodiments. Any one or more of the features of these embodiments may be combined with any one or more features of another example, embodiment, or aspect described herein.</p><p id="p-0064" num="0063">1. An isolated avian reovirus, wherein the isolated avian reovirus is the avian reovirus strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077, or a progeny or derivative thereof, wherein a progeny or derivative thereof has essentially the same biological and serological characteristics of the avian reovirus strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077.</p><p id="p-0065" num="0064">2. An isolated avian reovirus, wherein the isolated avian reovirus is the avian reovirus strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078, or a progeny or derivative thereof, wherein a progeny or derivative thereof has essentially the same biological and serological characteristics of the avian reovirus strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078.</p><p id="p-0066" num="0065">3. The isolated avian reovirus of embodiment 1 or 2, wherein the isolated avian reovirus comprises a Master Seed virus.</p><p id="p-0067" num="0066">4. The isolated avian reovirus of any one of embodiments 1 to 3, wherein the isolated avian reovirus is lyophilized, freeze dried, frozen, or an effervescent tablet.</p><p id="p-0068" num="0067">5. A composition comprising the isolated avian reovirus of any one of embodiments 1 to 4.</p><p id="p-0069" num="0068">6. The composition of embodiment 5 comprising an adjuvant.</p><p id="p-0070" num="0069">7. The composition of embodiment 5 or 6 comprising a pharmaceutically acceptable carrier.</p><p id="p-0071" num="0070">8. The composition of any one of embodiments 5 to 7, wherein the composition is formulated for intranasal, intraocular, oral, mucosal, intramuscular, subcutaneous, or in ovo administration.</p><p id="p-0072" num="0071">9. The composition of any one of embodiments 5 to 8, wherein the composition is formulated for spraying or aerolizing.</p><p id="p-0073" num="0072">10. A vaccine comprising the isolated avian reovirus of any one of embodiments 1 to 4 or the composition of any one of embodiments 5 to 9.</p><p id="p-0074" num="0073">11. The vaccine of embodiment 10, wherein the vaccine reduces the susceptibility of a bird of the order Galliformes to reovirus-induced viral arthritis/tenosynovitis.</p><p id="p-0075" num="0074">12. A vaccine for birds of the order Galliformes comprising an amount of the avian reovirus strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077, or a progeny or derivative thereof, sufficient to protect the birds from reovirus-induced viral arthritis/tenosynovitis, and a pharmaceutically acceptable carrier.</p><p id="p-0076" num="0075">13. The vaccine of embodiment 11 or 12, wherein the reovirus-induced viral arthritis/tenosynovitis is a variant group 1/genotype 5-induced viral arthritis/tenosynovitis.</p><p id="p-0077" num="0076">14. A vaccine for birds of the order Galliformes comprising an amount of the avian reovirus strain avian reovirus strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078, or a progeny or derivative thereof, sufficient to protect the birds from reovirus-induced viral arthritis/tenosynovitis, and a pharmaceutically acceptable carrier.</p><p id="p-0078" num="0077">15. The vaccine of embodiment 13 or 14, wherein the reovirus-induced viral arthritis/tenosynovitis is a variant group 2/genotype 1-induced viral arthritis/tenosynovitis.</p><p id="p-0079" num="0078">16. An effervescent tablet comprising an avian reovirus, composition, or vaccine of any one of embodiments 1 to 15.</p><p id="p-0080" num="0079">17. A method for reducing susceptibility of a bird of the order Galliformes against reovirus-induced viral arthritis/tenosynovitis, the method comprising administering to the bird an avian reovirus, composition, or vaccine of any one of embodiments 1 to 16.</p><p id="p-0081" num="0080">18. A method for protecting a bird of the order Galliformes against reovirus-induced viral arthritis/tenosynovitis, the method comprising administering to the bird an avian reovirus, composition, or vaccine of any one of embodiments 1 to 16.</p><p id="p-0082" num="0081">19. The method of embodiment 17 or 18, wherein the reovirus-induced viral arthritis/tenosynovitis is a variant group 1/genotype 5-induced viral arthritis/tenosynovitis.</p><p id="p-0083" num="0082">20. The method of embodiment 17 or 18, wherein the reovirus-induced viral arthritis/tenosynovitis is a variant group 2/genotype 1-induced viral arthritis/tenosynovitis.</p><p id="p-0084" num="0083">21. The method of any one of embodiments 17 to 20, wherein administration is intranasal, intraocular, oral, mucosal, intramuscular, or subcutaneous.</p><p id="p-0085" num="0084">22. The method of any one of embodiments 17 to 20, wherein administration comprises in ovo administration.</p><p id="p-0086" num="0085">23. The method of any one of embodiments 17 to 20, wherein the avian reovirus, composition, or vaccine is administered by aerosol.</p><p id="p-0087" num="0086">24. The method of any one of embodiments 17 to 20, wherein the avian reovirus, composition, or vaccine is administered by drinking water.</p><p id="p-0088" num="0087">25. The method of any one of embodiments 17 to 24, wherein administration comprises administration to a breeder hen or a rooster.</p><p id="p-0089" num="0088">26. A method of producing anti-reovirus antibodies in poultry, the method comprising administering an isolated avian reovirus, composition, or vaccine of any one of embodiments 1 to 16 to the bird.</p><p id="p-0090" num="0089">27. The method of any one of embodiments 17 to 26, wherein the bird is a chicken or turkey.</p><p id="p-0091" num="0090">28. A diagnostic kit comprising an isolated avian reovirus of any one of embodiments 1 to 4.</p><p id="p-0092" num="0091">29. A method of detecting exposure to an avian reovirus in a bird, the method comprising determining that an antisera sample obtained from the bird specifically binds to an avian reovirus of any one of embodiments 1 to 3.</p><p id="p-0093" num="0092">30. A hyperimmune sera to an avian reovirus of ay one of embodiments 1 to 3.</p><p id="p-0094" num="0093">31. An antibody that binds to an avian reovirus of any one of embodiments 1 to 3 and does not bind to avian reovirus strain S1133, 1733, 2408, and/or 2177.</p><p id="p-0095" num="0094">32. The antibody of embodiment 31, wherein the antibody is a monoclonal antibody.</p><p id="p-0096" num="0095">The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.</p><heading id="h-0005" level="1">EXAMPLES</heading><heading id="h-0006" level="1">Example 1</heading><heading id="h-0007" level="1">94826 C140&#x2014;Variant Group 1/Genotype 5 Avian Reovirus</heading><p id="p-0097" num="0096">The attenuated avian reovirus 94826 C140 was obtained by passaging the 94826 avian reovirus 140 times in chicken embryos. Attenuated avian reovirus 94826 C140 was deposited with the ATCC&#xae; under Patent Deposit Designation as PTA-126077 on Aug. 13, 2019. Attenuated avian reovirus 94826 C140 is also archived as PDRC ref: 121116 in the virus repository at the Poultry Diagnostic and Research Center (PDRC) at the University of Georgia, located at 953 College Station Road Athens Ga., 20602. The safety and efficacy of 94826 C140 as a live, attenuated reovirus vaccine is described in more detail in Example 3.</p><p id="p-0098" num="0097">The parental 94826 avian reovirus is a Group 1/Genotype 5 avian reovirus and is described in more detail International Application No. PCT/US2015/013449 (WO 2015/116778) and U.S. patent application Ser. No. 15/223,623, both of which are incorporated herein by reference.</p><heading id="h-0008" level="1">Example 2</heading><heading id="h-0009" level="1">96139 C140&#x2014;Variant Group 2/Genotype 1 Avian Reovirus</heading><p id="p-0099" num="0098">The attenuated avian reovirus 96139 C140 was obtained by passaging the 96139 avian reovirus 140 times in chicken embryos. Attenuated avian reovirus 96139 C140 was deposited with the ATCC&#xae; under Patent Deposit Designation as PTA-126078 on Aug. 13, 2019. Attenuated avian reovirus 9619 C140 is also archived as PDRC ref: 119812 in the virus repository at the Poultry Diagnostic and Research Center (PDRC) at the University of Georgia, located at 953 College Station Road Athens Ga., 20602. The safety and efficacy of 96139 C140 as a live, attenuated reovirus vaccine is described in more detail in Example 3.</p><p id="p-0100" num="0099">The parental 96139 avian reovirus is Group 2/Genotype 1 avian reovirus, is described in more detail International Application No. PCT/US2015/013449 (WO 2015/116778) and U.S. patent application Ser. No. 15/223,623, both of which are incorporated herein by reference and was deposited with the ATCC&#xae; under Patent Deposit Designation as PTA-125688 on Mar. 7, 2019.</p><heading id="h-0010" level="1">Example 3</heading><heading id="h-0011" level="1">Live Attenuated Reovirus Vaccine Candidates 94826 C140 and 96139 C140 Isolates</heading><p id="p-0101" num="0100">The 94826 C140 avian reovirus, a variant Group 1/Genotype 5 avian reovirus, is as described in Example 1.</p><p id="p-0102" num="0101">The 96139 C140 avian reovirus, a variant Group 2/Genotype 1 avian reovirus, is as described in Example 2. 96139 C140</p><heading id="h-0012" level="2">Embryo Passages</heading><p id="p-0103" num="0102">Both virus isolates were passaged successively in specific pathogen free (SPF) embryos via the chorioallantoic membrane (CAM) route of inoculation. Specifically, CAM from the original isolate was diluted 1:100 in sterile Minimal essential media (MEM) and 0.1 ml inoculated into the CAM of 9-11 day old SPF embryos. At 48 hours post-inoculation, embryos were refrigerated at 4 C for 4 hours and CAMs from embryos were collected, pooled, homogenized in virus transport media (VTM) using the Omni bead ruptor, clarified at 1500&#xd7;g and stored at &#x2212;80 until the next embryo passage.</p><heading id="h-0013" level="2">C140 Stock Titers</heading><p id="p-0104" num="0103">Stock titers for both 94826 C140 and 96139 C140 are shown in Table 1 below.</p><p id="p-0105" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>C140 stock titers represented as embryo </entry></row><row><entry>infectious dose 50 per ml</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="140pt" align="center"/><tbody valign="top"><row><entry/><entry>Virus</entry><entry>Titer (EID50/ml)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>94826 C140</entry><entry>10<sup>7.6</sup></entry></row><row><entry/><entry>96139 C140</entry><entry>10<sup>8.2</sup></entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0014" level="2">Identity Testing</heading><p id="p-0106" num="0104">Identity testing was performed every 10-20 embryo passages. Briefly, aliquots of CAM passages were submitted for reovirus Sigma CRT-PCR, sequenced and nucleotide and amino acid sequences compared to original and previous passages to confirm identity.</p><heading id="h-0015" level="2">Purity Testing</heading><p id="p-0107" num="0105">Purity testing was performed on the C140 stocks per guidelines set forth in 9 Code of Federal Regulations (9CFR) section 113.332 (9 CFR &#xa7; 113.332), as well as, by culture and RT-PCR/PCR methods.</p><p id="p-0108" num="0106">Bacteria, fungi, and mold culture indicated that both the 94826 C140 and 96139 C140 stocks were negative for bacteria, fungus, and mold by culture.</p><p id="p-0109" num="0107">PCR indicated that both 94826 C140 and 96139 C140 stocks were negative for <i>Mycoplasma gallisepticum </i>(MG) and <i>Mycoplasma synoviae </i>(MS).</p><p id="p-0110" num="0108">PCR/RT-PCR for extraneous viruses indicated that both the 94826 C140 and 96139 C140 stocks were negative for extraneous avian viruses.</p><p id="p-0111" num="0109">The results for lymphoid leukosis contamination testing of stock viruses per guidelines set forth in 9 CFR &#xa7; 113.332 (b)(2)(3) is shown in Table 2, below and indicated that both the 94826 C140 and 96139 C140 stocks are free of leukosis contamination.</p><p id="p-0112" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="259pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Results of lymphoid leukosis contamination testing</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><colspec colname="5" colwidth="49pt" align="left"/><tbody valign="top"><row><entry/><entry/><entry>Plasma tested</entry><entry>REO ELISA</entry><entry>AGP with stock</entry></row><row><entry>Group</entry><entry># birds<sup>A</sup></entry><entry>by VI/LLAG<sup>B</sup></entry><entry>(IDEXX)</entry><entry>reovirus</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="28pt" align="char" char="."/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><colspec colname="5" colwidth="49pt" align="left"/><tbody valign="top"><row><entry>94826 C140 @10<sup>4.5 </sup>EID50 IM<sup>C</sup></entry><entry>10</entry><entry>NEG</entry><entry>3801</entry><entry>POS</entry></row><row><entry>96139 C140 @ 10<sup>4.5 </sup>EID50IM</entry><entry>10</entry><entry>NEG</entry><entry>3521</entry><entry>POS</entry></row><row><entry>ALV-A Positive control</entry><entry>5</entry><entry>POS</entry><entry>NT</entry><entry>NT</entry></row><row><entry>ALV-B Positive control</entry><entry>5</entry><entry>POS</entry><entry>NT</entry><entry>NT</entry></row><row><entry>Negative controls</entry><entry>5</entry><entry>NEG</entry><entry>NEG</entry><entry>NEG</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry namest="1" nameend="5" align="left" id="FOO-00001"><sup>A</sup>3-week-old SPF birds</entry></row><row><entry namest="1" nameend="5" align="left" id="FOO-00002"><sup>B</sup>Virus Isolation in DF-1 cells and LLAG ELISA; tested in duplicate</entry></row><row><entry namest="1" nameend="5" align="left" id="FOO-00003"><sup>C</sup>Intramuscular Injection in breast muscle</entry></row></tbody></tgroup></table></tables></p><heading id="h-0016" level="2">Safety Testing</heading><p id="p-0113" num="0110">The CAM passages 140 (C140) for both isolates were safety tested per the guidelines outlined in the 9 Code of Federal Regulations (9CFR) section 113.332.</p><heading id="h-0017" level="2">Experimental Outline</heading><p id="p-0114" num="0111">Bird source<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0112">Parent stock (broiler type birds) from Aviagen</li>        <li id="ul0002-0002" num="0113">Breeders vaccinated with commercial live and inactivated S1133</li>        <li id="ul0002-0003" num="0114">Broiler chicks negative for reovirus 94826 and 96139 antibodies</li>    </ul>    </li></ul></p><p id="p-0115" num="0115">Safety test per 9 CFR</p><p id="p-0116" num="0116">Parameters for evaluation per 9 CFR<ul id="ul0003" list-style="none">    <li id="ul0003-0001" num="0000">    <ul id="ul0004" list-style="none">        <li id="ul0004-0001" num="0117">94826 C140 (VG1/GT5) 10<sup>4 </sup>EID50/0.2 ml [29 chicks]</li>        <li id="ul0004-0002" num="0118">94826 C140 (VG1/GT5) 10<sup>5 </sup>EID50/0.2 ml [30 chicks]</li>        <li id="ul0004-0003" num="0119">96139 C140 (VG2/GT1) 10<sup>4 </sup>EID50/0.2 ml [30 chicks]</li>        <li id="ul0004-0004" num="0120">96139 C140 (VG2/GT1) 10<sup>5 </sup>EID50/0.2 ml [30 chicks]</li>        <li id="ul0004-0005" num="0121">Monitored daily for 21 days</li>        <li id="ul0004-0006" num="0122">Evaluation for lameness, tendon/hock swelling</li>        <li id="ul0004-0007" num="0123">Mortality</li>    </ul>    </li></ul></p><p id="p-0117" num="0124">Results of the 10&#xd7; evaluation in 1-day-old commercial broilers negative for antibodies to 94826 and 96139 are shown in Table 3, below. Results showed that no clinical signs or macroscopic lesions were observed in broilers subcutaneously injected 10<sup>4 </sup>EID50 or 10<sup>5 </sup>EID50 dose of 94826 or 96139 during the 21 day post-vaccination period of evaluation. Vaccines are considered safe for use in 1-day-old broilers at these doses.</p><p id="p-0118" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="301pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Results of 10X safety study in 1-day-old broilers</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="98pt" align="left"/><colspec colname="3" colwidth="105pt" align="left"/><tbody valign="top"><row><entry/><entry>Daily observations</entry><entry>21 days-of-age</entry></row><row><entry>Vaccine dose</entry><entry>Clinical signs</entry><entry>Post-mortem examination</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>94826 C140 (VG1/GT5) IQ<sup>4</sup></entry><entry>No clinical signs observed in</entry><entry>No macroscopic lesions observed in</entry></row><row><entry>EID50/0.2 ml</entry><entry>29/29 birds</entry><entry>29/29 birds</entry></row><row><entry>94826 C140 (VG1/GT5) 10<sup>5</sup></entry><entry>No clinical signs observed in</entry><entry>No macroscopic lesions observed in</entry></row><row><entry>EID50/0.2 ml</entry><entry>30/30 birds</entry><entry>30/30 birds</entry></row><row><entry>96139 C140 (VG2/GT1) IQ<sup>4</sup></entry><entry>No clinical signs observed in</entry><entry>No macroscopic lesions observed in</entry></row><row><entry>EID50/0.2 ml</entry><entry>30/30 birds</entry><entry>30/30 birds</entry></row><row><entry>96139 C140 (VG2/GT1) 10<sup>5</sup></entry><entry>No clinical signs observed in</entry><entry>No macroscopic lesions observed in</entry></row><row><entry>EID50/0.2 ml</entry><entry>30/30 birds</entry><entry>30/30 birds</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0119" num="0125">Results of the 10&#xd7; evaluation in 28-day-of age commercial broilers negative for antibodies to 94826 and 96139 are shown in Table 4, below. Results showed no clinical signs or macroscopic lesions were observed in broilers subcutaneously injected 10<sup>4 </sup>EID50 or 10<sup>5 </sup>EID50 dose of 94826 or 96139 during the 21 day post-vaccination period of evaluation. Vaccines are considered safe for use in 28-day-of-age broilers at these doses.</p><p id="p-0120" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="301pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Results of 10X safety study in 28-day-of-age broilers</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="98pt" align="left"/><colspec colname="3" colwidth="105pt" align="left"/><tbody valign="top"><row><entry/><entry>Daily observations</entry><entry>21 days-of-age</entry></row><row><entry>Vaccine dose</entry><entry>Clinical signs</entry><entry>Post-mortem examination</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>94826 C140 (VG1/GT5) IQ<sup>4</sup></entry><entry>No clinical signs observed in</entry><entry>No macroscopic lesions observed in</entry></row><row><entry>EID50/0.2 ml</entry><entry>30/30 birds</entry><entry>30/30 birds</entry></row><row><entry>94826 C140 (VG1/GT5) 10<sup>5</sup></entry><entry>No clinical signs observed in</entry><entry>No macroscopic lesions observed in</entry></row><row><entry>EID50/0.2 ml</entry><entry>29/29 birds</entry><entry>29/29 birds</entry></row><row><entry>96139 C140 (VG2/GT1) 10<sup>4</sup></entry><entry>No clinical signs observed in</entry><entry>No macroscopic lesions observed in</entry></row><row><entry>EID50/0.2 ml</entry><entry>30/30 birds</entry><entry>30/30 birds</entry></row><row><entry>96139 C140 (VG2/GT1) 10<sup>5</sup></entry><entry>No clinical signs observed in</entry><entry>No macroscopic lesions observed in</entry></row><row><entry>EID50/0.2 ml</entry><entry>30/30 birds</entry><entry>30/30 birds</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0018" level="2">Efficacy Testing</heading><p id="p-0121" num="0126">The C140 stocks were evaluated for efficacy per 9 CFR 113.332 (4)(c)(1,2,3) Efficacy testing in 1-day-of-age broilers negative for reovirus antibodies to 94826 and 96139</p><p id="p-0122" num="0127">Vaccinated/Subcutaneous injection<ul id="ul0005" list-style="none">    <li id="ul0005-0001" num="0000">    <ul id="ul0006" list-style="none">        <li id="ul0006-0001" num="0128">94826 C140 (VG1/GT5) 10<sup>2.5 </sup>EID50/0.2 ml [31 chicks]</li>        <li id="ul0006-0002" num="0129">94826 C140 (VG1/GT5) 10<sup>3 </sup>EID50/0.2 ml [31 chicks]</li>        <li id="ul0006-0003" num="0130">96139 C140 (VG2/GT1) 10<sup>2.5 </sup>EID50/0.2 ml [30 chicks]</li>        <li id="ul0006-0004" num="0131">96139 C140 (VG2/GT1) 10<sup>3 </sup>EID50/0.2 ml [30 chicks]</li>        <li id="ul0006-0005" num="0132">Unvaccinated Controls        <ul id="ul0007" list-style="none">            <li id="ul0007-0001" num="0133">20 chicks placed in isolation units at 1-day-of-age for unvaccinated/challenged controls</li>        </ul>        </li>        <li id="ul0006-0006" num="0134">21-days-of-age (vaccinated/subQ and unvaccinated)        <ul id="ul0008" list-style="none">            <li id="ul0008-0001" num="0135">All groups challenged via footpad injection with 10<sup>4 </sup>EID50/0.05 ml 94826 Li7 or 96139 Li5 (parent viruses)</li>        </ul>        </li>        <li id="ul0006-0007" num="0136">Observed daily for 14 days        <ul id="ul0009" list-style="none">            <li id="ul0009-0001" num="0137">Mortality</li>            <li id="ul0009-0002" num="0138">Depression</li>            <li id="ul0009-0003" num="0139">Lameness/limping</li>            <li id="ul0009-0004" num="0140">Swollen footpads and/or tendons</li>        </ul>        </li>    </ul>    </li></ul></p><p id="p-0123" num="0141">Results from efficacy testing in 1-day-of-age broilers are shown in Table 5, below. Results showed that 1-day-of-age chicks vaccinated with 10<sup>25 </sup>or 10<sup>3 </sup>EID50 per dose were protected following challenge with homologous parent viruses.</p><p id="p-0124" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="266pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 5</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Results from efficacy testing in 1-day-of-age broilers</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="77pt" align="left"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="70pt" align="left"/><tbody valign="top"><row><entry>Group</entry><entry>Footpad Challenge</entry><entry/><entry/></row><row><entry>Vaccinated at 1 doa<sup>A</sup></entry><entry>21 doa-10<sup>4 </sup>EID<sup>B </sup>50/dose</entry><entry># birds</entry><entry>Clinical signs at 6 dpc<sup>C</sup></entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>94826 C140 10<sup>2.5 </sup>EID50/dose</entry><entry>94826 Li7</entry><entry>31</entry><entry>31/31 NCS<sup>D</sup></entry></row><row><entry>94826 C140 10<sup>3.0 </sup>EID50/dose</entry><entry>94826 Li7</entry><entry>30</entry><entry>30/30 NCS</entry></row><row><entry>96139 C140 10<sup>2.5 </sup>EID50/dose</entry><entry>96139 Li5</entry><entry>31</entry><entry>31/31 NCS</entry></row><row><entry>96139 C140 10<sup>3.0 </sup>EID50/dose</entry><entry>96139 Li5</entry><entry>30</entry><entry>30/30 NCS</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry namest="1" nameend="4" align="left" id="FOO-00004"><sup>A</sup>days-of-age</entry></row><row><entry namest="1" nameend="4" align="left" id="FOO-00005"><sup>B</sup>embryo infectious dose</entry></row><row><entry namest="1" nameend="4" align="left" id="FOO-00006"><sup>C</sup>days post challenge</entry></row><row><entry namest="1" nameend="4" align="left" id="FOO-00007"><sup>D</sup>no clinical signs</entry></row></tbody></tgroup></table></tables></p><p id="p-0125" num="0142">Results from unvaccinated/parent virus challenged broilers are shown in Table 6, below. Results indicated that the efficacy test was valid based clinical signs observed in unvaccinated/challenged broilers.</p><p id="p-0126" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 6</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Results from unvaccinated/parent virus challenged broilers</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="63pt" align="left"/><colspec colname="3" colwidth="28pt" align="left"/><colspec colname="4" colwidth="77pt" align="left"/><tbody valign="top"><row><entry/><entry>Footpad Challenge </entry><entry/><entry/></row><row><entry/><entry>at 21 days of</entry><entry/><entry/></row><row><entry/><entry>age with 10<sup>4 </sup>EID<sup>A</sup></entry><entry>#</entry><entry/></row><row><entry>Group</entry><entry>50/dose</entry><entry>birds</entry><entry>Clinical signs at 6 dpc<sup>B</sup></entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>Unvaccinated</entry><entry>94826 Li7</entry><entry>10</entry><entry>10/10</entry></row><row><entry/><entry/><entry/><entry>redness/swelling</entry></row><row><entry>Unvaccinated</entry><entry>96139 Li5</entry><entry>10</entry><entry>9/10 redness/swelling</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0127" num="0143">Results from the back titration of C140 stocks for 1-day-of age efficacy study-aliquots of diluted C140 stocks (10<sup>2.5 </sup>and 10<sup>3 </sup>EID50/dose) titrated in embryos (5 replicates) are shown in Table 7, below.</p><p id="p-0128" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 7</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Titration of C140 reoviruses used in 1-day-of-age efficacy study.</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="56pt" align="left"/><colspec colname="1" colwidth="161pt" align="center"/><tbody valign="top"><row><entry/><entry>Titer EID50/dose</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="28pt" align="left"/><colspec colname="3" colwidth="28pt" align="left"/><colspec colname="4" colwidth="28pt" align="left"/><colspec colname="5" colwidth="28pt" align="left"/><colspec colname="6" colwidth="28pt" align="left"/><colspec colname="7" colwidth="21pt" align="left"/><tbody valign="top"><row><entry>Virus</entry><entry>REP 1</entry><entry>REP 2</entry><entry>REP 3</entry><entry>REP 4</entry><entry>REP 5</entry><entry>GMT</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry>94826 C140</entry><entry>10<sup>2.7</sup></entry><entry>10<sup>2.1</sup></entry><entry>10<sup>2.1</sup></entry><entry>10<sup>2.5</sup></entry><entry>10<sup>2.5</sup></entry><entry>10<sup>2.4</sup></entry></row><row><entry>10<sup>2.5 </sup>EID50/dose</entry></row><row><entry>94826 C140</entry><entry>10<sup>3.0</sup></entry><entry>10<sup>3.1</sup></entry><entry>10<sup>2.9</sup></entry><entry>10<sup>3.0</sup></entry><entry>10<sup>2.9</sup></entry><entry>10<sup>3.0</sup></entry></row><row><entry>10<sup>3 </sup>EID50/dose</entry></row><row><entry>96139 C140</entry><entry>10<sup>2.9</sup></entry><entry>10<sup>2.5</sup></entry><entry>10<sup>2.5</sup></entry><entry>10<sup>2.5</sup></entry><entry>10<sup>2.6</sup></entry><entry>10<sup>2.6</sup></entry></row><row><entry>10<sup>2.5 </sup>EID50/dose</entry></row><row><entry>96139 C140</entry><entry>10<sup>2.9</sup></entry><entry>10<sup>2.9</sup></entry><entry>10<sup>3.1</sup></entry><entry>10<sup>3.1</sup></entry><entry>10<sup>3.1</sup></entry><entry>10<sup>3.0</sup></entry></row><row><entry>10<sup>3 </sup>EID50/dose</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry namest="1" nameend="7" align="left" id="FOO-00008">GMT = geometric mean titer</entry></row></tbody></tgroup></table></tables></p><heading id="h-0019" level="2">Summary of Efficacy Testing in 1-Day-of-Age Broilers</heading><p id="p-0129" num="0144">Day-of-age vaccination with 94826 C140 or 96139 C140 at 10<sup>25 </sup>and 10<sup>3 </sup>doses protected against clinical signs following footpad challenge with parent viruses.</p><p id="p-0130" num="0145">Unvaccinated/challenged controls fell within acceptable limits outlined in outlined in 9CFR 113.332 (4)(c)(3) for both parent viruses.</p><p id="p-0131" num="0146">Testing in 1-day-old broilers was acceptable per 9CFR guidelines.</p><p id="p-0132" num="0147">The complete disclosure of all patents, patent applications, and publications, and electronically available material (including, for instance, nucleotide sequence submissions in, e.g., GenBank and RefSeq, and amino acid sequence submissions in, e.g., SwissProt, PIR, PRF, PDB, and translations from annotated coding regions in GenBank and RefSeq) cited herein are incorporated by reference. In the event that any inconsistency exists between the disclosure of the present application and the disclosure(s) of any document incorporated herein by reference, the disclosure of the present application shall govern. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.</p><?detailed-description description="Detailed Description" end="tail"?></description><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. An isolated avian reovirus, wherein the isolated avian reovirus is the avian reovirus strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077, or a progeny or derivative thereof, wherein a progeny or derivative thereof has essentially the same biological and serological characteristics of the avian reovirus strain 94826 C140 deposited at the ATCC under Patent Designation PTA-126077.</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. An isolated avian reovirus, wherein the isolated avian reovirus is the avian reovirus strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078, or a progeny or derivative thereof, wherein a progeny or derivative thereof has essentially the same biological and serological characteristics of the avian reovirus strain 96139 C140 deposited at the ATCC under Patent Designation PTA-126078.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The isolated avian reovirus of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the isolated avian reovirus comprises a Master Seed virus.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The isolated avian reovirus of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the isolated avian reovirus is lyophilized, freeze dried, frozen, or an effervescent tablet.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. A composition comprising the isolated avian reovirus of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The composition of <claim-ref idref="CLM-00005">claim 5</claim-ref> comprising an adjuvant.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The composition of <claim-ref idref="CLM-00005">claim 5</claim-ref> comprising a pharmaceutically acceptable carrier.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. The composition of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the composition is formulated:<claim-text>for intranasal, intraocular, oral, mucosal, intramuscular, subcutaneous, or in ovo administration; or</claim-text><claim-text>for spraying or aerolizing.</claim-text></claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. (canceled)</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. A vaccine comprising the isolated avian reovirus of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The vaccine of <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein the vaccine reduces the susceptibility of a bird of the order Galliformes to reovirus-induced viral arthritis/tenosynovitis.</claim-text></claim><claim id="CLM-12-16" num="12-16"><claim-text><b>12</b>-<b>16</b>. (canceled)</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. A method for reducing susceptibility of a bird of the order Galliformes against reovirus-induced viral arthritis/tenosynovitis, the method comprising administering to the bird an avian reovirus of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. A method for protecting a bird of the order Galliformes against reovirus-induced viral arthritis/tenosynovitis, the method comprising administering to the bird an avian reovirus of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-19-20" num="19-20"><claim-text><b>19</b>-<b>20</b>. (canceled)</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The method of <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein administration comprises:<claim-text>intranasal, intraocular, oral, mucosal, intramuscular, or subcutaneous administration;</claim-text><claim-text>in ovo administration;</claim-text><claim-text>administration by aerosol; or</claim-text><claim-text>administration by drinking water.</claim-text></claim-text></claim><claim id="CLM-22-24" num="22-24"><claim-text><b>22</b>-<b>24</b>. (canceled)</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. The method of <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein administration comprises administration to a breeder hen or a rooster.</claim-text></claim><claim id="CLM-00026" num="00026"><claim-text><b>26</b>. A method of producing anti-reovirus antibodies in poultry, the method comprising administering an isolated avian reovirus of <claim-ref idref="CLM-00001">claim 1</claim-ref> to the bird.</claim-text></claim><claim id="CLM-00027" num="00027"><claim-text><b>27</b>. The method of <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein the bird is a chicken or turkey.</claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. A diagnostic kit comprising an isolated avian reovirus of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. A method of detecting exposure to an avian reovirus in a bird, the method comprising determining that an antisera sample obtained from the bird specifically binds to an avian reovirus of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. A hyperimmune sera to an avian reovirus of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. An antibody that binds to an avian reovirus of <claim-ref idref="CLM-00001">claim 1</claim-ref> and does not bind to avian reovirus strain S1133, 1733, 2408, and/or 2177.</claim-text></claim><claim id="CLM-00032" num="00032"><claim-text><b>32</b>. (canceled)</claim-text></claim></claims></us-patent-application>